Pellegrino Musto
#130,869
Most Influential Person Now
Researcher
Pellegrino Musto's AcademicInfluence.com Rankings
Pellegrino Mustocomputer-science Degrees
Computer Science
#5749
World Rank
#6068
Historical Rank
Computational Linguistics
#869
World Rank
#882
Historical Rank
Machine Learning
#1636
World Rank
#1658
Historical Rank
Artificial Intelligence
#1872
World Rank
#1904
Historical Rank
Download Badge
Computer Science
Pellegrino Musto's Degrees
- PhD Computer Science University of Milan
- Bachelors Computer Science University of Milan
Similar Degrees You Can Earn
Why Is Pellegrino Musto Influential?
(Suggest an Edit or Addition)Pellegrino Musto's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Revised International Staging System for Multiple Myeloma: A Report From International Myeloma Working Group. (2015) (1274)
- Oral melphalan and prednisone chemotherapy plus thalidomide compared with melphalan and prednisone alone in elderly patients with multiple myeloma: randomised controlled trial (2006) (803)
- BRAF mutations in hairy-cell leukemia. (2011) (763)
- Autologous transplantation and maintenance therapy in multiple myeloma. (2014) (642)
- Cardiovascular events and intensity of treatment in polycythemia vera. (2013) (621)
- Geriatric assessment predicts survival and toxicities in elderly myeloma patients: an International Myeloma Working Group report. (2015) (532)
- Lenalidomide Maintenance After Autologous Stem-Cell Transplantation in Newly Diagnosed Multiple Myeloma: A Meta-Analysis. (2017) (441)
- Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: a randomized controlled trial. (2010) (404)
- Efficacy and safety of once-weekly bortezomib in multiple myeloma patients. (2010) (370)
- Oral melphalan, prednisone, and thalidomide in elderly patients with multiple myeloma: updated results of a randomized controlled trial. (2008) (368)
- Clinical characteristics and risk factors associated with COVID-19 severity in patients with haematological malignancies in Italy: a retrospective, multicentre, cohort study (2020) (339)
- Intermediate-dose melphalan improves survival of myeloma patients aged 50 to 70: results of a randomized controlled trial. (2004) (320)
- Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network. (2007) (318)
- Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter case-control study. (2003) (302)
- Epoxy-silica particulate nanocomposites: Chemical interactions, reinforcement and fracture toughness (2005) (294)
- Bortezomib-thalidomide-dexamethasone is superior to thalidomide-dexamethasone as consolidation therapy after autologous hematopoietic stem cell transplantation in patients with newly diagnosed multiple myeloma. (2012) (292)
- European Myeloma Network Guidelines for the Management of Multiple Myeloma-related Complications (2015) (283)
- Major tumor shrinking and persistent molecular remissions after consolidation with bortezomib, thalidomide, and dexamethasone in patients with autografted myeloma. (2010) (270)
- Thalidomide for previously untreated elderly patients with multiple myeloma: meta-analysis of 1685 individual patient data from 6 randomized clinical trials. (2011) (261)
- Complete response correlates with long-term progression-free and overall survival in elderly myeloma treated with novel agents: analysis of 1175 patients. (2011) (258)
- ABVD compared with BEACOPP compared with CEC for the initial treatment of patients with advanced Hodgkin's lymphoma: results from the HD2000 Gruppo Italiano per lo Studio dei Linfomi Trial. (2009) (251)
- Blastic plasmacytoid dendritic cell neoplasm with leukemic presentation: an Italian multicenter study (2013) (245)
- Second primary malignancies with lenalidomide therapy for newly diagnosed myeloma: a meta-analysis of individual patient data. (2014) (239)
- Bortezomib-melphalan-prednisone-thalidomide followed by maintenance with bortezomib-thalidomide compared with bortezomib-melphalan-prednisone for initial treatment of multiple myeloma: updated follow-up and improved survival. (2014) (198)
- Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma. (2007) (181)
- Bortezomib as induction before autologous transplantation, followed by lenalidomide as consolidation-maintenance in untreated multiple myeloma patients. (2010) (177)
- A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma (2008) (173)
- Tandem autologous/reduced-intensity conditioning allogeneic stem-cell transplantation versus autologous transplantation in myeloma: long-term follow-up. (2011) (171)
- A randomized double‐blind placebo‐controlled study with subcutaneous recombinant human erythropoietin in patients with low‐risk myelodysplastic syndromes (1998) (169)
- Flow cytometric characterization of human umbilical cord blood lymphocytes: immunophenotypic features. (1998) (163)
- A novel spectroscopic approach to investigate transport processes in polymers: the case of water–epoxy system (2001) (156)
- Carfilzomib, cyclophosphamide, and dexamethasone in patients with newly diagnosed multiple myeloma: a multicenter, phase 2 study. (2014) (133)
- High serum levels of extracellular vesicles expressing malignancy-related markers are released in patients with various types of hematological neoplastic disorders (2015) (133)
- Continuous Therapy Versus Fixed Duration of Therapy in Patients With Newly Diagnosed Multiple Myeloma. (2015) (132)
- High prevalence of hepatitis B virus infection in B-cell non-Hodgkin's lymphoma. (2006) (131)
- The use of FDG-PET in the initial staging of 142 patients with follicular lymphoma: a retrospective study from the FOLL05 randomized trial of the Fondazione Italiana Linfomi. (2013) (129)
- Efficacy of low-dose thalidomide and dexamethasone as first salvage regimen in multiple myeloma. (2004) (129)
- Salvage therapy with thalidomide in patients with advanced relapsed/refractory multiple myeloma. (2002) (127)
- Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. (2014) (122)
- The clinical relevance and management of monoclonal gammopathy of undetermined significance and related disorders: recommendations from the European Myeloma Network (2014) (120)
- Polyimide-silica nanocomposites: spectroscopic, morphological and mechanical investigations (2004) (118)
- Prophylaxis against infections with low-dose intravenous immunoglobulins (IVIG) in chronic lymphocytic leukemia. Results of a crossover study. (1996) (118)
- Bortezomib, doxorubicin and dexamethasone in advanced multiple myeloma. (2008) (116)
- Clinical management of myelodysplastic syndromes: update of SIE, SIES, GITMO practice guidelines. (2010) (113)
- 18F-FDG PET/CT focal, but not osteolytic, lesions predict the progression of smoldering myeloma to active disease (2016) (112)
- Safety and efficacy of thalidomide in patients with myelofibrosis with myeloid metaplasia (2001) (110)
- Azacitidine for the treatment of patients with acute myeloid leukemia (2012) (110)
- High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program (2009) (110)
- Impact of a new dosing regimen of epoetin alfa on quality of life and anemia in patients with low-risk myelodysplastic syndrome (2005) (109)
- High risk of early resistant relapse for leukaemic patients with presence of multidrug resistance associated P‐glycoprotein positive cells in complete remission (1991) (105)
- Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients (2012) (103)
- Different impact of NOTCH1 and SF3B1 mutations on the risk of chronic lymphocytic leukemia transformation to Richter syndrome (2012) (103)
- Serum level of the soluble form of the CD30 molecule identifies patients with Hodgkin's disease at high risk of unfavorable outcome. (1998) (101)
- Darbepoetin alpha for the treatment of anaemia in low‐intermediate risk myelodysplastic syndromes (2005) (100)
- Clinico‐prognostic implications of simultaneous increased serum levels of soluble CD23 and β2‐microglobulin in B‐cell chronic lymphocytic leukemia (1999) (99)
- Expression of the c-met proto-oncogene and its ligand, hepatocyte growth factor, in Hodgkin disease. (2001) (98)
- Valproic Acid at Therapeutic Plasma Levels May Increase 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Syndromes (2009) (98)
- Azacitidine for the treatment of lower risk myelodysplastic syndromes (2010) (97)
- Quantitative flow cytometry for the differential diagnosis of leukemic B‐cell chronic lymphoproliferative disorders (2000) (94)
- CD38 Expression Correlates with Adverse Biological Features and Predicts Poor Clinical Outcome in B-Cell Chronic Lymphocytic Leukemia (2001) (93)
- Minimal Residual Disease after Conventional Treatment Significantly Impacts on Progression-Free Survival of Patients with Follicular Lymphoma: The FIL FOLL05 Trial (2014) (92)
- Vibrational Spectroscopy Evidence for the Dual Nature of Water Sorbed into Epoxy Resins (2000) (91)
- Bisphosphonate-associated osteonecrosis of the jaw: a review of 35 cases and an evaluation of its frequency in multiple myeloma patients (2007) (90)
- Thermal-Oxidative Degradation of Epoxy and Epoxy-Bismaleimide Networks: Kinetics and Mechanism (2001) (88)
- Efficacy and safety of bortezomib in patients with plasma cell leukemia (2007) (88)
- The transport of water in a tetrafunctional epoxy resin by near-infrared Fourier transform spectroscopy (2000) (88)
- Pamidronate versus observation in asymptomatic myeloma: final results with long-term follow-up of a randomized study (2011) (87)
- Incidence, Risk Factors and Outcome of Pre-engraftment Gram-Negative Bacteremia After Allogeneic and Autologous Hematopoietic Stem Cell Transplantation: An Italian Prospective Multicenter Survey (2017) (87)
- Biological and Clinical Relevance of miRNA Expression Signatures in Primary Plasma Cell Leukemia (2013) (86)
- Probing the molecular interactions in the diffusion of water through epoxy and epoxy–bismaleimide networks (2002) (86)
- MiRNAs and piRNAs from bone marrow mesenchymal stem cell extracellular vesicles induce cell survival and inhibit cell differentiation of cord blood hematopoietic stem cells: a new insight in transplantation (2015) (85)
- Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. (2010) (84)
- Melphalan 200 mg/m(2) versus melphalan 100 mg/m(2) in newly diagnosed myeloma patients: a prospective, multicenter phase 3 study. (2010) (83)
- Oral melphalan at diagnosis hampers adequate collection of peripheral blood progenitor cells in multiple myeloma. (2002) (82)
- Long-term results of the GIMEMA VEL-03-096 trial in MM patients receiving VTD consolidation after ASCT: MRD kinetics' impact on survival (2014) (82)
- Two novel imatinib‐responsive PDGFRA fusion genes in chronic eosinophilic leukaemia (2007) (81)
- Oral melphalan, prednisone, and thalidomide for newly diagnosed patients with myeloma (2005) (81)
- Properties of poly(urea-formaldheyde) microcapsules containing an epoxy resin (2007) (80)
- A Study by Raman, near-infrared and dynamic-mechanical spectroscopies on the curing behaviour, molecular structure and viscoelastic properties of epoxy/anhydride networks (2007) (80)
- European myeloma network recommendations on diagnosis and management of patients with rare plasma cell dyscrasias (2018) (80)
- Hydrogen bonding in polybenzimidazole/poly(ether imide) blends: a spectroscopic study (1991) (80)
- Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program. (2013) (79)
- Rituximab for warm‐type idiopathic autoimmune hemolytic anemia: a retrospective study of 11 adult patients (2007) (78)
- Safety and efficacy of bortezomib‐based regimens for multiple myeloma patients with renal impairment: a retrospective study of Italian Myeloma Network GIMEMA (2010) (77)
- Frontline chemotherapy with bortezomib-containing combinations improves response rate and survival in primary plasma cell leukemia: a retrospective study from GIMEMA Multiple Myeloma Working Party. (2012) (76)
- An interpenetrated system based on a tetrafunctional epoxy resin and a thermosetting bismaleimide: Structure–properties correlation (1998) (75)
- Double Autologous Stem Cell Transplantation Significantly Prolongs Progression-Free Survival and Overall Survival in Comparison with Single Autotransplantation in Newly Diagnosed Multiple Myeloma: An Analysis of Phase 3 EMN02/HO95 Study (2017) (75)
- Distinct lncRNA transcriptional fingerprints characterize progressive stages of multiple myeloma (2016) (75)
- Lenalidomide and low-dose dexamethasone for newly diagnosed primary plasma cell leukemia (2014) (74)
- Thermoplastic Molecular Sieves (2000) (71)
- How cyclodextrin incorporation affects the properties of protein-loaded PLGA-based microspheres: the case of insulin/hydroxypropyl-beta-cyclodextrin system. (2005) (71)
- Normal vibrational analysis of the syndiotactic polystyrene s(2/1)2 helix. (2009) (71)
- Efficacy of carfilzomib lenalidomide dexamethasone (KRd) with or without transplantation in newly diagnosed myeloma according to risk status: Results from the FORTE trial. (2019) (69)
- F‐18 FDG PET/CT quantization parameters as predictors of outcome in patients with diffuse large B‐cell lymphoma (2014) (69)
- Second primary malignancies in multiple myeloma: an overview and IMWG consensus. (2016) (69)
- Time to onset of bisphosphonate-related osteonecrosis of the jaws: a multicentre retrospective cohort study. (2017) (68)
- Primary plasma cell leukemia: a retrospective multicenter study of 73 patients. (2011) (68)
- Bortezomib and zoledronic acid on angiogenic and vasculogenic activities of bone marrow macrophages in patients with multiple myeloma. (2010) (67)
- Incidence, risk factors and management of pleural effusions during dasatinib treatment in unselected elderly patients with chronic myelogenous leukaemia (2013) (66)
- Molecular spectrum of BRAF, NRAS and KRAS gene mutations in plasma cell dyscrasias: implication for MEK-ERK pathway activation (2015) (66)
- Functionalization of an amorphous ethylene‐propylene copolymer by free radical initiated grafting of unsaturated molecules (1984) (66)
- The prognostic role of post-induction FDG-PET in patients with follicular lymphoma: a subset analysis from the FOLL05 trial of the Fondazione Italiana Linfomi (FIL). (2014) (66)
- Autoimmune Cytopenias in Chronic Lymphocytic Leukemia (2013) (66)
- MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report (2017) (65)
- Positive effects on hematopoiesis in patients with myelodysplastic syndrome receiving deferasirox as oral iron chelation therapy: a brief review. (2011) (65)
- Probing by time-resolved FTIR spectroscopy mass transport, molecular interactions, and conformational ordering in the system chloroform-syndiotactic polystyrene (2002) (65)
- Guest Conformation and Diffusion into Amorphous and Emptied Clathrate Phases of Syndiotactic Polystyrene (1998) (65)
- Evaluation by Fourier Transform Infrared Spectroscopy of the different crystalline forms in syndiotactic polystyrene samples (1997) (64)
- MicroRNAs as New Biomarkers for Diagnosis and Prognosis, and as Potential Therapeutic Targets in Acute Myeloid Leukemia (2018) (64)
- Bulk functionalization of ethylene-propylene copolymers I. Influence of temperature and processing on the reaction kinetics (1987) (64)
- Serum levels of cytokines and soluble antigens in polytransfused patients with beta-thalassemia major: relationship to immune status. (1994) (63)
- A plasmonic nanostructure fabricated by electron beam lithography as a sensitive and highly homogeneous SERS substrate for bio-sensing applications (2016) (63)
- Genome‐wide analysis of primary plasma cell leukemia identifies recurrent imbalances associated with changes in transcriptional profiles (2013) (62)
- Thalidomide therapy for myelodysplastic syndromes: current status and future perspectives. (2004) (61)
- Blood cell flow cytometry in paroxysmal nocturnal hemoglobinuria: a tool for measuring the extent of the PNH clone. (1996) (61)
- Tetrafunctional epoxy resins: Modeling the curing kinetics based on FTIR spectroscopy data (1999) (60)
- Efficacy and safety of bendamustine for the treatment of patients with recurring Hodgkin lymphoma (2013) (59)
- Cellular expression and serum circulating levels of CD23 in B-cell chronic lymphocytic leukemia. Implications for prognosis. (1996) (58)
- High rate of remissions in chronic myelomonocytic leukemia treated with 5-azacytidine: results of an Italian retrospective study (2013) (57)
- Outcome prediction of diffuse large B-cell lymphomas associated with hepatitis C virus infection: a study on behalf of the Fondazione Italiana Linfomi (2014) (56)
- Photo-Oxidation of High Performance Epoxy Networks: Correlation between the Molecular Mechanisms of Degradation and the Viscoelastic and Mechanical Response (2008) (55)
- Urea‐Formaldehyde Microcapsules Containing an Epoxy Resin: Influence of Reaction Parameters on the Encapsulation Yield (2006) (55)
- Clathrate Phase in Syndiotactic Polystyrene Gels (2002) (54)
- Microstructural features, diffusion and molecular relaxations in polyimide/silica hybrids (2006) (53)
- Quality of life and physicians' perception in myelodysplastic syndromes. (2012) (53)
- FTIR spectra of pure helical crystalline phases of syndiotactic polystyrene (2006) (52)
- Transcriptional Characterization of a Prospective Series of Primary Plasma Cell Leukemia Revealed Signatures Associated with Tumor Progression and Poorer Outcome (2013) (52)
- Whole-exome sequencing of primary plasma cell leukemia discloses heterogeneous mutational patterns (2015) (52)
- Clinical results of recombinant erythropoietin in transfusion‐dependent patients with refractory multiple myeloma: role of cytokines and monitoring of erythropoiesis (1997) (52)
- Observational study of chronic myeloid leukemia Italian patients who discontinued tyrosine kinase inhibitors in clinical practice (2019) (51)
- Fourier transform infrared spectroscopy of the polymorphic forms of syndiotactic polystyrene (1990) (51)
- Efficacy of a single, weekly dose of recombinant erythropoietin in myelodysplastic syndromes (2003) (51)
- Human umbilical cord blood: immunophenotypic heterogeneity of CD34+ hematopoietic progenitor cells. (1996) (50)
- Azacitidine frontline therapy for unfit acute myeloid leukemia patients: clinical use and outcome prediction. (2015) (50)
- Hepatitis C virus infection and monoclonal gammopathies not associated with cryoglobulinemia. (1996) (49)
- Anisotropic Guest Diffusion in the δ Crystalline Host Phase of Syndiotactic Polystyrene: Transport Kinetics in Films with Three Different Uniplanar Orientations of the Host Phase (2006) (48)
- Water transport in densely crosslinked networks: A comparison between epoxy systems having different interactive characters (2006) (48)
- Hepatitis C virus infection: a new bridge between hematologists and gastroenterologists? (1996) (48)
- Prevalence of hepatitis C virus infection in lymphoproliferative diseases other than B-cell non-Hodgkin's lymphoma, and in myeloproliferative diseases: an Italian Multi-Center case-control study. (2004) (48)
- Outcome of therapy-related myeloid neoplasms treated with azacitidine (2012) (48)
- Toughness enhancement of polyimides by in situ generation of silica particles (2004) (47)
- Stem cell mobilization in patients with newly diagnosed multiple myeloma after lenalidomide induction therapy (2011) (47)
- Two-dimensional FTIR spectroscopy studies on the thermal-oxidative degradation of epoxy and epoxy-bis(maleimide) networks (2003) (47)
- Carfilzomib-Lenalidomide-Dexamethasone (KRd) Induction-Autologous Transplant (ASCT)-Krd Consolidation Vs KRd 12 Cycles Vs Carfilzomib-Cyclophosphamide-Dexamethasone (KCd) Induction-ASCT-KCd Consolidation: Analysis of the Randomized Forte Trial in Newly Diagnosed Multiple Myeloma (NDMM) (2018) (46)
- On the Molecular Mechanism of H2O Diffusion into Polyimides : A Vibrational Spectroscopy Investigation (2007) (46)
- Normal vibrational analysis of a trans-planar syndiotactic polystyrene chain. (2007) (46)
- Amyloid in bone marrow smears of patients affected by multiple myeloma (2010) (45)
- COVID‐19 elicits an impaired antibody response against SARS‐CoV‐2 in patients with haematological malignancies (2021) (45)
- Role of BCL2L10 methylation and TET2 mutations in higher risk myelodysplastic syndromes treated with 5-Azacytidine (2011) (44)
- Toughening of a highly cross‐linked epoxy resin by reactive blending with bisphenol A polycarbonate. I. FTIR spectroscopy (1994) (44)
- Reduced intensity conditioning for allograft after cytoreductive autograft in metastatic breast cancer (2005) (44)
- Toughening of highly crosslinked epoxy resins by reactive blending with bisphenol A polycarbonate. II: Yield and fracture behavior (1994) (44)
- Photoisomerization patterns based on molecular complex phases of syndiotactic polystyrene (2007) (44)
- Survival Analysis of Newly Diagnosed Transplant-Eligible Multiple Myeloma Patients in the Randomized Forte Trial (2020) (44)
- Pamidronate Reduces Skeletal Events but does not Improve Progression-free Survival in Early-stage Untreated Myeloma: Results of a Randomized Trial (2003) (44)
- Autologous transplant vs oral chemotherapy and lenalidomide in newly diagnosed young myeloma patients: a pooled analysis (2017) (43)
- Second malignancies after treatment of diffuse large B-cell non-Hodgkin’s lymphoma: a GISL cohort study (2008) (42)
- Characterization and prognostic relevance of circulating microvesicles in chronic lymphocytic leukemia (2016) (42)
- Second primary malignancies in multiple myeloma: an overview and IMWG consensus. (2018) (42)
- Monoclonal B-Cell Lymphocytosis (2014) (42)
- SPONTANEOUS REMISSION IN ACUTE MYELOID LEUKAEMIA: A ROLE FOR ENDOGENOUS PRODUCTIONOF TUMOUR NECROSIS FACTOR AND INTERLEUKIN‐2? (1994) (41)
- Rapid loss of response after withdrawal of treatment with azacitidine: a case series in patients with higher‐risk myelodysplastic syndromes or chronic myelomonocytic leukemia (2013) (41)
- Chlorinated Guest Orientation and Mobility in Clathrate Structures Formed with Syndiotactic Polystyrene (2003) (41)
- CD117 (c-kit) is a restricted antigen of acute myeloid leukemia and characterizes early differentiative levels of M5 FAB subtype. (1998) (41)
- Overall Survival Benefit for Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance with Bortezomib-Thalidomide (VMPT-VT) Versus Bortezomib-Melphalan-Prednisone (VMP) in Newly Diagnosed Multiple Myeloma Patients (2012) (41)
- Outcome of 82 chronic myeloid leukemia patients treated with nilotinib or dasatinib after failure of two prior tyrosine kinase inhibitors (2013) (40)
- Low serum levels of tumor necrosis factor and interleukin-1 beta in myelodysplastic syndromes responsive to recombinant erythropoietin. (1994) (40)
- Low-dose subcutaneous alemtuzumab in refractory chronic lymphocytic leukaemia (CLL): results of a prospective, single-arm multicentre study (2009) (39)
- High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling (2020) (39)
- Salvage therapy with lenalidomide and dexamethasone in relapsed primary plasma cell leukemia. (2008) (39)
- Advanced mast cell disease: an Italian Hematological Multicenter experience (2008) (39)
- Protein pathway activation mapping of brain metastasis from lung and breast cancers reveals organ type specific drug target activation. (2011) (38)
- Molecular spectrum of TP53 mutations in plasma cell dyscrasias by next generation sequencing: an Italian cohort study and overview of the literature (2016) (38)
- A compendium of DIS3 mutations and associated transcriptional signatures in plasma cell dyscrasias (2015) (38)
- Thermosetting bismaleimide/reactive rubber blends: Curing kinetics and mechanical behavior (1997) (38)
- Four proteins governing overangiogenic endothelial cell phenotype in patients with multiple myeloma are plausible therapeutic targets (2012) (38)
- Hepatitis C virus infection and B-cell non-Hodgkin's lymphomas: more than a simple association. (2002) (38)
- Mesenchymal Stem Cell Derived Extracellular Vesicles: A Role in Hematopoietic Transplantation? (2017) (37)
- Polyimide/silica hybrids via the sol-gel route: High performance materials for the new technological challenges (2009) (37)
- Decision analysis of allogeneic hematopoietic stem cell transplantation for patients with myelodysplastic syndrome stratified according to the revised International Prognostic Scoring System (2017) (36)
- Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) Followed by Maintenance with Bortezomib and Thalidomide for Initial Treatment of Elderly Multiple Myeloma Patients. (2009) (36)
- Lenalidomide−prednisone induction followed by lenalidomide−melphalan−prednisone consolidation and lenalidomide−prednisone maintenance in newly diagnosed elderly unfit myeloma patients (2013) (35)
- A shorter time to the first treatment may be predicted by the absolute number of regulatory T‐cells in patients with Rai stage 0 chronic lymphocytic leukemia (2012) (35)
- The iron chelator deferasirox affects redox signalling in haematopoietic stem/progenitor cells (2015) (34)
- Effect of the chemical structure of aromatic polyimides on their thermal aging, relaxation behavior and mechanical properties (2012) (34)
- Knockdown of miR-128a induces Lin28a expression and reverts myeloid differentiation blockage in acute myeloid leukemia (2017) (34)
- Multiple myeloma: comparison of two dose-intensive melphalan regimens (100 vs 200 mg/m2) (2004) (34)
- Advanced routes for polymer toughening (1996) (34)
- Compendium of FAM46C gene mutations in plasma cell dyscrasias (2016) (34)
- Safety and efficacy of bortezomib-melphalan-prednisone-thalidomide followed by bortezomib-thalidomide maintenance (VMPT-VT) versus bortezomib-melphalan-prednisone (VMP) in untreated multiple myeloma patients with renal impairment. (2011) (34)
- Extracellular Vesicles: A New Prospective in Crosstalk between Microenvironment and Stem Cells in Hematological Malignancies (2018) (34)
- Regulatory T-Cell Modulation by Green Tea in Chronic Lymphocytic Leukemia (2013) (34)
- A Prospective Randomized Trial of Oral Melphalan, Prednisone, Thalidomide (MPT) vs Oral Melphalan, Prednisone (MP): An Interim Analysis. (2004) (33)
- Safety and efficacy of rituximab plus bendamustine in relapsed or refractory diffuse large B-cell lymphoma patients: an Italian retrospective multicenter study (2016) (33)
- Analysis of Frequency and Risk Factors for Developing Bisphosphonate Associated Osteonecrosis of the Jaw. (2005) (33)
- Adult and childhood acute lymphoblastic leukemia: clinico-biological differences based on CD34 antigen expression. (1997) (33)
- PROPHYLAXIS AGAINST INFECTIONS WITH INTRAVENOUS IMMUN0GLOBULINS IN MULTIPLE MYELOMA (1995) (32)
- Surface Enhanced Raman Spectroscopy for Quantitative Analysis: Results of a Large-Scale European Multi-Instrument Interlaboratory Study (2020) (32)
- Isothermal Guest Desorption from Crystalline and Amorphous Phases of Syndiotactic Polystyrene (1999) (32)
- Primary plasma cell leukemia: consensus definition by the International Myeloma Working Group according to peripheral blood plasma cell percentage (2021) (32)
- Thalidomide plus dexamethasone is an effective salvage regimen for myeloma patients relapsing after autologous transplant (2005) (32)
- Octupolar Metastructures for a Highly Sensitive, Rapid, and Reproducible Phage-Based Detection of Bacterial Pathogens by Surface-Enhanced Raman Scattering. (2017) (32)
- Engineering poly(ethylene oxide) buccal films with cyclodextrin: a novel role for an old excipient? (2013) (32)
- Vaccination against influenza in multiple myeloma. (1997) (31)
- Assessing the suitability of polylactic acid flexible films for high pressure pasteurization and sterilization of packaged foodstuff (2012) (31)
- Nanochemical fabrication of a graphene oxide-based nanohybrid for label-free optical sensing with fiber optics (2014) (31)
- Combining gravimetric and vibrational spectroscopy measurements to quantify first- and second-shell hydration layers in polyimides with different molecular architectures. (2012) (31)
- Dasatinib is safe and effective in unselected chronic myeloid leukaemia elderly patients resistant/intolerant to imatinib. (2011) (31)
- Minimal residual disease after transplantation or lenalidomide-based consolidation in myeloma patients: a prospective analysis (2016) (31)
- Age influences initial dose and compliance to imatinib in chronic myeloid leukemia elderly patients but concomitant comorbidities appear to influence overall and event-free survival. (2014) (31)
- Extracellular Vesicles in Hematological Malignancies: From Biology to Therapy (2017) (31)
- Predictive parameters for mobilized peripheral blood CD34+ progenitor cell collection in patients with hematological malignancies (1998) (30)
- Shortening the discharging time after total hip replacement under combined spinal/epidural anesthesia by actively warming the patient during surgery. (1999) (30)
- Bulk functionalization of ethylene–propylene copolymers. III. Structural and superreticular order investigations (1989) (30)
- Pressure control ventilation and minitracheotomy in treating severe flail chest trauma (1995) (30)
- Autoimmune hemolytic anemia during alpha interferon treatment in nine patients with hematological diseases. (1996) (30)
- Standard dose and prolonged administration of azacitidine are associated with improved efficacy in a real‐world group of patients with myelodysplastic syndrome or low blast count acute myeloid leukemia (2016) (30)
- Improving the photo-oxidative stability of epoxy resins by use of functional POSS additives: A spectroscopic, mechanical and morphological study ☆ (2012) (30)
- Thalidomide abolishes transfusion-dependence in selected patients with myelodysplastic syndromes. (2002) (30)
- Reactive rubbers as toughening agents for thermoset polyester resins. Molecular analysis by FTIR and fracture behavior of the resulting blends (1993) (30)
- Time-resolved Fourier transform infrared spectroscopy, gravimetry, and thermodynamic modeling for a molecular level description of water sorption in poly(ε-caprolactone). (2014) (30)
- Regulatory T-cells in chronic lymphocytic leukemia: actor or innocent bystander? (2013) (29)
- Regulatory T Cells and Their Prognostic Relevance in Hematologic Malignancies (2017) (29)
- A randomized trial with melphalan and prednisone versus melphalan and prednisone plus thalidomide in newly diagnosed multiple myeloma patients not eligible for autologous stem cell transplant (2011) (29)
- Regenerative Recycling of Automotive Polymer Components: Poly(propylene) Based Car Bumpers (2003) (28)
- Electroless Gold-Modified Diatoms as Surface-Enhanced Raman Scattering Supports (2016) (28)
- Non-equilibrium compressible lattice theories accounting for hydrogen bonding interactions: Modelling water sorption thermodynamics in fluorinated polyimides (2012) (28)
- Bulk functionalization of ethylene-propylene copolymers. II: Influence of the initiator concentration and of the copolymer composition and chain microstructure on the reaction kinetics (1989) (28)
- A multicenter, randomized clinical trial comparing zoledronic acid versus observation in patients with asymptomatic myeloma (Cancer (2008) 113, (1588-1595)) (2008) (27)
- Natural ageing of automotive polymer components: Characterisation of new and used poly(propylene) based car bumpers (2002) (27)
- Targeting the p53-MDM2 interaction by the small-molecule MDM2 antagonist Nutlin-3a: a new challenged target therapy in adult Philadelphia positive acute lymphoblastic leukemia patients (2016) (27)
- Skin transport of PEGylated poly(ε-caprolactone) nanoparticles assisted by (2-hydroxypropyl)-β-cyclodextrin. (2015) (27)
- Management of infectious complications in multiple myeloma patients: Expert panel consensus-based recommendations. (2019) (27)
- P53-MDM2 Pathway: Evidences for A New Targeted Therapeutic Approach in B-Acute Lymphoblastic Leukemia (2016) (27)
- Antiviral treatment in patients with indolent B-cell lymphomas associated with HCV infection: a study of the Fondazione Italiana Linfomi. (2014) (27)
- A novel reactive liquid rubber with maleimide end groups for the toughening of unsaturated polyester resins (1996) (27)
- Flow cytometric characterization of CD34+ hematopoietic progenitor cells in mobilized peripheral blood and bone marrow of cancer patients. (1996) (26)
- The anti-CD20 monoclonal antibody rituximab to treat acquired haemophilia A. (2016) (26)
- Gastric Normal Adjacent Mucosa Versus Healthy and Cancer Tissues: Distinctive Transcriptomic Profiles and Biological Features (2019) (26)
- Cure kinetics and ultimate properties of a tetrafunctional epoxy resin toughened by a perfluoro-ether oligomer (2001) (26)
- A Pilot Characterization of Human Lung NSCLC by Protein Pathway Activation Mapping (2012) (26)
- Outcome of paraosseous extra-medullary disease in newly diagnosed multiple myeloma patients treated with new drugs (2019) (26)
- CD27 in B-cell chronic lymphocytic leukemia. Cellular expression, serum release and correlation with other soluble molecules belonging to nerve growth factor receptors (NGFr) superfamily. (1998) (26)
- The Curing Process and Moisture Transport in a Tetrafunctional Epoxy Resin as Investigated by FT-NIR Spectroscopy (2000) (26)
- Physical Gelation of Syndiotactic Polystyrene in the Presence of Large Molar Volume Solvents Induced by Volatile Guests of Clathrate Phases (2003) (26)
- Modifications of erythropoiesis in myelodysplastic syndromes treated with recombinant erythropoietin as evaluated by soluble transferrin receptor, high fluorescence reticulocytes and hypochromic erythrocytes. (1994) (26)
- Water Sorption Thermodynamics in Glassy and Rubbery Polymers: Modeling the Interactional Issues Emerging from FTIR Spectroscopy (2013) (26)
- Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience (2012) (26)
- Reactivity, viscoelastic behaviour and mechanical performances of hybrid systems based on epoxy resins and reactive polyhedral oligosilsesquioxanes ☆ (2009) (25)
- A Phase II Trial on Alpha-Interferon α IFN) Effect in Patients with Monoclonal IgM Gammopathy (1994) (25)
- Thalidomide therapy in adult patients with myelodysplastic syndrome (2006) (25)
- Temperature switch and thermally induced optical bistability in a PDLC (1998) (25)
- Therapeutic approaches for newly diagnosed multiple myeloma patients in the era of novel drugs (2010) (25)
- A prognostic model for patients with lymphoma and COVID-19: a multicentre cohort study (2021) (25)
- Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. (2020) (25)
- Host−Guest Interactions and Crystalline Structure Evolution in Clathrate Phases Formed by Syndiotactic Polystyrene and 1,2-Dichloroethane: A Two-Dimensional FTIR Spectroscopy Investigation (2005) (25)
- Short progression‐free survival in myeloma patients receiving rituximab as maintenance therapy after autologous transplantation (2003) (25)
- Local Structure and Dynamics of Water Absorbed in Poly(ether imide): A Hydrogen Bonding Anatomy. (2017) (25)
- Response to recombinant erythropoietin alpha, without the adjunct of granulocyte-colony stimulating factor, is associated with a longer survival in patients with transfusion-dependent myelodysplastic syndromes. (2010) (25)
- Circulating Regulatory T Cells in “Clinical” Monoclonal B-Cell Lymphocytosis (2011) (25)
- A polymer network of unsaturated polyester and bismaleimide resins: 1. Kinetics, mechanism and molecular structure (1996) (25)
- A Simple Score, Based On Geriatric Assessment, Improves Prediction of Survival, and Risk Of Serious Adverse Events In Elderly Newly Diagnosed Multiple Myeloma Patients (2013) (25)
- No cross-resistance after sequential use of romiplostim and eltrombopag in chronic immune thrombocytopenic purpura. (2013) (24)
- Predicting failure of hematopoietic stem cell mobilization before it starts: the predicted poor mobilizer (pPM) score (2018) (24)
- Management of Patients With Hematologic Malignancies During the COVID-19 Pandemic: Practical Considerations and Lessons to Be Learned (2020) (24)
- Prognostic or predictive value of circulating cytokines and angiogenic factors for initial treatment of multiple myeloma in the GIMEMA MM0305 randomized controlled trial (2019) (24)
- Adding growth factors or interleukin-3 to erythropoietin has limited effects on anemia of transfusion-dependent patients with myelodysplastic syndromes unresponsive to erythropoietin alone. (2001) (24)
- Bendamustine with or without rituximab in the treatment of relapsed chronic lymphocytic leukaemia: an Italian retrospective study (2011) (24)
- Phase 1/2 study of weekly carfilzomib, cyclophosphamide, dexamethasone in newly diagnosed transplant-ineligible myeloma (2018) (24)
- Prognostic relevance of serum thymidine kinase in primary myelodysplastic syndromes: relationship to development of acute myeloid leukaemia (1995) (24)
- Toughening of highly crosslinked thermosetting resins by blending with thermoplastic polyether imide (1993) (24)
- CD69 expression in B-cell chronic lymphocytic leukemia: a new prognostic marker ? (2001) (23)
- Bortezomib, melphalan, prednisone (VMP) versus melphalan, prednisone, thalidomide (MPT) in elderly newly diagnosed multiple myeloma patients: A retrospective case‐matched study (2014) (23)
- Clinical Relevance of Immunocytochemical Detection of Multidrug-Resistance-Associated P-Glycoprotein in Hematologic Malignancies (1990) (23)
- Tandem Autologous(ASCT)/ Allogeneic Reduced Intensity Conditioning Transplantation (RIC) with Identical Sibling Donor Versus ASCT in Previously Untreated Multiple Myeloma (MM): Long Term Follow up of a Prospective Controlled Trial by the EBMT. (2009) (23)
- Intermediate-dose melphalan (100 mg/m2)/bortezomib/thalidomide/dexamethasone and stem cell support in patients with refractory or relapsed myeloma. (2006) (22)
- Cytological and histological detection of amyloid deposits in bone marrow of patients affected by multiple myeloma (2011) (22)
- Insights into defibrotide: an updated review (2009) (22)
- CD200 included in a 4‐marker modified Matutes score provides optimal sensitivity and specificity for the diagnosis of chronic lymphocytic leukaemia (2018) (22)
- Towards a predictive thermodynamic description of sorption processes in polymers: The synergy between theoretical EoS models and vibrational spectroscopy (2020) (22)
- A Phase III Study of Enoxaparin Versus Low-Dose Warfarin Versus Aspirin as Thromboprophylaxis for Patients with Newly Diagnosed Multiple Myeloma Treated up-Front with Thalidomide-Containing Regimens (2008) (22)
- Molecular Classification and Pharmacogenetics of Primary Plasma Cell Leukemia: An Initial Approach toward Precision Medicine (2015) (22)
- MET dysregulation is a hallmark of aggressive disease in multiple myeloma patients (2014) (22)
- Dielectric behavior of biopolymer based composites containing multi wall carbon nanotubes: Effect of filler content and aspect ratio (2015) (22)
- Primary plasma cell leukemia in the era of new drugs: has something changed? (2012) (22)
- Lipegfilgrastim in the management of chemotherapy-induced neutropenia of cancer patients (2016) (22)
- Dose-intensive melphalan with stem cell support (CM regimen) is effective and well tolerated in elderly myeloma patients. (2000) (22)
- Fludarabine, cyclophosphamide, and rituximab in patients with advanced, untreated, indolent B‐cell nonfollicular lymphomas (2012) (21)
- Spectroscopic Investigation of Host−Guest Interactions into Clathrate Phases of Syndiotactic Polystyrene Containing Chlorinated Compounds (2000) (21)
- Conventional induction treatments do not influence overall survival in multiple myeloma (1997) (21)
- Bortezomib, Melphalan, Prednisone and Thalidomide Followed by Maintenance with Bortezomib and Thalidomide (VMPT-VT) for Initial Treatment of Elderly Multiple Myeloma Patients: Updated Follow-up and Impact of Prognostic Factors (2010) (21)
- Considerations in the treatment of multiple myeloma: a consensus statement from Italian experts (2009) (21)
- Thy-1 (CDw90) and c-kit receptor (CD117) expression on CD34+ hematopoietic progenitor cells: a five dimensional flow cytometric study. (1998) (21)
- Diffusion of water and ammonia through polyimide-silica bicontinuous nanocomposites: interactions and reactions (2005) (21)
- Heterogeneity of Response to Imatinib-Mesylate (Glivec) in Patients with Hypereosinophilic Syndrome: Implications for Dosing and Pathogenesis (2004) (21)
- Primary Plasma Cell Leukemia: Identity Card 2016 (2016) (21)
- Possible Multiple Myeloma Dedifferentiation Following Thalidomide Therapy: A Report of Four Cases (2004) (21)
- Iron‐chelating therapy with deferasirox in transfusion‐dependent, higher risk myelodysplastic syndromes: a retrospective, multicentre study (2017) (21)
- Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell’Adulto Multip (2015) (21)
- A new method of preparation of a rubber‐modified polyamide directly during caprolactam polymerization (1985) (21)
- Inability of activated cord blood T lymphocytes to perform Th1-like and Th2-like responses: implications for transplantation. (1999) (20)
- ITACA: A new validated international erythropoietic stimulating agent‐response score that further refines the predictive power of previous scoring systems (2017) (20)
- Clinical Outcomes of 217 Patients with Acute Erythroleukemia According to Treatment Type and Line: A Retrospective Multinational Study (2017) (20)
- Maintenance Therapy With Lenalidomide Significantly Improved Survival Of Yong Newly Diagnosed Multiple Myeloma Patients (2013) (20)
- Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: an Italian multicentric survey (2014) (20)
- Polyimide‐Silica Hybrids: Spectroscopy, Morphology and Mechanical Properties (2001) (20)
- Carfilzomib-lenalidomide-dexamethasone (KRd) vs carfilzomib-cyclophosphamide-dexamethasone (KCd) induction: Planned interim analysis of the randomized FORTE trial in newly diagnosed multiple myeloma (NDMM). (2017) (20)
- Early mortality in myeloma patients treated with first-generation novel agents thalidomide, lenalidomide, bortezomib at diagnosis: A pooled analysis. (2018) (20)
- Rituximab-based pre-emptive treatment of molecular relapse in follicular and mantle cell lymphoma (2013) (20)
- Melphalan/prednisone/lenalidomide (MPR) versus high-dose melphalan and autologous transplantation (MEL200) plus lenalidomide maintenance or no maintenance in newly diagnosed multiple myeloma (MM) patients. (2013) (20)
- Melphalan: old and new uses of a still master drug for multiple myeloma (2007) (20)
- Metal defects in HKUST-1 MOF revealed by vibrational spectroscopy: a combined quantum mechanical and experimental study (2020) (20)
- An update on extracellular vesicles in multiple myeloma: a focus on their role in cell-to-cell cross-talk and as potential liquid biopsy biomarkers (2019) (20)
- Rayleigh scattering by graphene-oxide in syndiotactic polystyrene aerogels (2014) (20)
- Deferasirox chelation therapy in patients with transfusion‐dependent MDS: a ‘real‐world’ report from two regional Italian registries: Gruppo Romano Mielodisplasie and Registro Basilicata (2015) (20)
- Combination of erythropoietin and thalidomide for the treatment of anemia in patients with myelodysplastic syndromes. (2006) (19)
- Confocal Raman imaging, FTIR spectroscopy and kinetic modelling of the zinc oxide/stearic acid reaction in a vulcanizing rubber (2013) (19)
- Once-weekly versus twice-weekly carfilzomib in patients with newly diagnosed multiple myeloma: a pooled analysis of two phase I/II studies (2019) (19)
- Epha3 acts as proangiogenic factor in multiple myeloma (2017) (19)
- Inefficacy of imatinib-mesylate in sporadic, aggressive systemic mastocytosis. (2004) (19)
- Chromosome 1 abnormalities in elderly patients with newly diagnosed multiple myeloma treated with novel therapies (2014) (19)
- The (68)Ge phantom-based FDG-PET site qualification program for clinical trials adopted by FIL (Italian Foundation on Lymphoma). (2016) (19)
- Diffuse B-Large Cell Lymphomas (DBLCL) with Hepatitis-C Virus (HCV) Infection: Clinical Outcome and Preliminary Results of a Pilot Study Combining R-CHOP with Antiviral Therapy. (2005) (19)
- Morphologically Typical and Atypical B-Cell Chronic Lymphocytic Leukemias Display a Different Pattern of Surface Antigenic Density (2001) (19)
- CPX-351 treatment in secondary acute myeloblastic leukemia is effective and improves the feasibility of allogeneic stem cell transplantation: results of the Italian compassionate use program (2020) (18)
- Fournier’s Gangrene Complicating Hematologic Malignancies: a Case Report and Review of Licterature (2013) (18)
- A Pyrazolo[3,4-d]pyrimidine compound inhibits Fyn phosphorylation and induces apoptosis in natural killer cell leukemia (2016) (18)
- An Italian retrospective study on the routine clinical use of low‐dose alemtuzumab in relapsed/refractory chronic lymphocytic leukaemia patients (2012) (18)
- Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the First Interim Analysis of the Phase 2 EMN12/HOVON129 Study (2019) (18)
- Impact of Gain and Amplification of 1q in Newly Diagnosed Multiple Myeloma Patients Receiving Carfilzomib-Based Treatment in the Forte Trial (2020) (18)
- Acute promyelocytic leukemia in patients aged over 60 years: multicenter experience of 34 consecutive unselected patients. (2010) (18)
- Evaluation of the Amount and Composition of the Polymer-Rich and Polymer-Poor Phases of Syndiotactic Polystyrene Gels with Binary Solvent Mixtures (2003) (18)
- A Prospective, Randomized, Phase III Study of Melphalan 200 mg/m2 (MEL200) Versus Melphalan 100 mg/m2 (MEL100) in Newly Diagnosed Myeloma Patients. (2006) (18)
- Maleated polyisobutylene: A novel toughener for unsaturated polyester resins (1995) (18)
- Real life experience with frontline azacitidine in a large series of older adults with acute myeloid leukemia stratified by MRC/LRF score: results from the expanded international E-ALMA series (E-ALMA+) (2018) (17)
- Bortezomib (Velcade) for progressive myeloma after autologous stem cell transplantation and thalidomide. (2006) (17)
- A Randomized Phase 3 Trial Of Melphalan-Lenalidomide-Prednisone (MPR) Or Cyclophosphamide-Prednisone-Lenalidomide (CPR) Vs Lenalidomide Plus Dexamethsone (Rd) In Elderly Newly Diagnosed Multiple Myeloma Patients (2013) (17)
- All-trans retinoic acid in combination with alpha-interferon and dexamethasone for advanced multiple myeloma. (1997) (17)
- Monoclonal antibodies in relapsed/refractory myeloma: updated evidence from clinical trials, real-life studies, and meta-analyses (2020) (17)
- Compatibilizing polyimide/silica hybrids by alkoxisilane-terminated oligoimides: Morphology–Properties relationships (2011) (17)
- Prognosis of chronic myelomonocytic leukemia. (1996) (16)
- Lenalidomide and its role in the management of multiple myeloma (2008) (16)
- Molecular Mechanism of H2O Diffusion into Polyimides: A Model Based on Dual Mobility with Instantaneous Local Nonlinear Equilibrium (2008) (16)
- Lenalidomide and low‐dose dexamethasone (Rd) versus bortezomib, melphalan, prednisone (VMP) in elderly newly diagnosed multiple myeloma patients: A comparison of two prospective trials (2017) (16)
- Myelodysplastic disorders carrying both isolated del(5q) and JAK2V617F mutation: concise review, with focus on lenalidomide therapy (2014) (16)
- Pamidronate reduces skeletal events but does not improve progression-free survival in early-stage untreated myeloma: results of a randomized trial. (2003) (16)
- Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: final results of a phase II study conducted by the Fondazione Italiana Linfomi (2016) (16)
- A new supertough epoxy formulation with high crosslinking density (1993) (16)
- Regulatory T-Cells in Chronic Lymphocytic Leukemia and Autoimmune Diseases (2012) (16)
- Molecular and mechanical characterization of reactive ethylene-propylene elastomers and their use in PA6-based blends (1992) (16)
- Inefficacy of clarithromycin in advanced multiple myeloma: a definitive report. (2002) (16)
- Elotuzumab, lenalidomide, and dexamethasone as salvage therapy for patients with multiple myeloma: Italian, multicenter, retrospective clinical experience with 300 cases outside of controlled clinical trials (2020) (16)
- Inflammatory Cells in Diffuse Large B Cell Lymphoma (2020) (16)
- Progress in the Treatment of Primary Plasma Cell Leukemia. (2016) (16)
- Infection control in patients with myelodysplastic syndromes who are candidates for active treatment: Expert panel consensus-based recommendations. (2019) (16)
- Clinico-prognostic implications of increased levels of soluble CD54 in the serum of B-cell chronic lymphocytic leukemia patients. Results of a multivariate survival analysis. (1997) (15)
- Adverse drug reactions after intravenous rituximab infusion are more common in hematologic malignancies than in autoimmune disorders and can be predicted by the combination of few clinical and laboratory parameters: results from a retrospective, multicenter study of 374 patients (2017) (15)
- Combined therapy with amifostine plus erythropoietin for the treatment of myelodysplastic syndromes. (2002) (15)
- Prognostic relevance of oxidative stress measurement in chronic lymphocytic leukaemia (2017) (15)
- Serum Beta2-Microglobulin in Malignant Lymphoproliferative Disorders (1988) (15)
- Diffusion in polymers as investigated by two-dimensional correlation spectroscopy: The H2O/PCL system (2014) (15)
- Validation of vacuum-based refrigerated system for biobanking tissue preservation: analysis of cellular morphology, protein stability, and RNA quality. (2014) (15)
- Future in the Past: Azorella glabra Wedd. as a Source of New Natural Compounds with Antiproliferative and Cytotoxic Activity on Multiple Myeloma Cells (2018) (15)
- Effective autologous peripheral blood stem cell transplantation in plasma cell leukemia followed by T-large granular lymphocyte expansion: a case report. (1996) (15)
- Soluble transferrin receptor in beta-thalassaemia (1993) (15)
- Oncocytic nonsecretory multiple myeloma. A clinicopathologic study of a case and review of the literature. (1996) (15)
- An update on biology, diagnosis and treatment of primary plasma cell leukemia (2019) (15)
- Hyperspectral Raman imaging of human prostatic cells: An attempt to differentiate normal and malignant cell lines by univariate and multivariate data analysis. (2017) (15)
- Functionalized Gold Nanoparticles as Biosensors for Monitoring Cellular Uptake and Localization in Normal and Tumor Prostatic Cells (2018) (15)
- Primary plasma cell leukemia 2.0: advances in biology and clinical management (2016) (15)
- Methanol diffusion in polyimides: A molecular description☆ (2014) (14)
- Erythroid response and decrease of WT1 expression after proteasome inhibition by bortezomib in myelodysplastic syndromes. (2011) (14)
- Reactive blending of thermosets: Molecular, morphological and mechanical analysis (1994) (14)
- Efficacy of bortezomib, lenalidomide and dexamethasone (VRD) in secondary plasma cell leukaemia (2012) (14)
- First-line therapy with either bortezomib-melphalan-prednisone or lenalidomide-dexamethasone followed by lenalidomide for transplant-ineligible multiple myeloma patients: a pooled analysis of two randomized trials (2019) (14)
- SERS spectroscopy for the therapeutic drug monitoring of the anticancer drug 6-Mercaptopurine: Molecular and kinetic studies (2021) (14)
- The role of ether-functionalized ionic liquids in the sol-gel process: effects on the initial alkoxide hydrolysis steps. (2015) (14)
- TWO DOSE-INTENIVE MELPHALAN REGIMENS (100 MG/M2 VERSUS 200 MG/M2) IN MULTIPLE MYELOMA PATIENTS (2003) (14)
- Engineered plasmonic Thue-Morse nanostructures for LSPR detection of the pesticide Thiram (2017) (14)
- Gene expression profiling of normal thyroid tissue from patients with thyroid carcinoma (2016) (14)
- Aberrant activation of ROS1 represents a new molecular defect in chronic myelomonocytic leukemia. (2013) (14)
- On the unexpected non-monotonic profile of specific volume observed in PCL/CO2 solutions (2015) (14)
- Impact of BCR-ABL mutations on response to dasatinib after imatinib failure in elderly patients with chronic-phase chronic myeloid leukemia (2012) (14)
- Granulocyte colony-stimulating factor and erythropoietin for the anemia of myelodysplastic syndromes: a real improvement with respect to erythropoietin alone? [letter; comment] (1994) (13)
- Effects of High Pressure Treatments on Polymeric Films for Flexible Food Packaging (2014) (13)
- Are "early" and "late" T-acute lymphoblastic leukemias different diseases? A single center study of 34 patients. (1996) (13)
- Do we need to distinguish exosomes from microvesicles in hematological malignancies? (2017) (13)
- Minimal Residual Disease Evaluation By Multiparameter Flow Cytometry and Next Generation Sequencing in the Forte Trial for Newly Diagnosed Multiple Myeloma Patients (2019) (13)
- Are maintenance and continuous therapies indicated for every patient with multiple myeloma? (2016) (13)
- Global methylation patterns in primary plasma cell leukemia. (2018) (13)
- Infrared Spectroscopy of Polybenzimidazole in the Dry and Hydrate Forms: A Combined Experimental and Computational Study (2018) (13)
- Total body computed tomography scan in the initial work‐up of Binet stage A chronic lymphocytic leukemia patients: Results of the prospective, multicenter O‐CLL1‐GISL study (2013) (13)
- Water Sorption Thermodynamics in Polymer Matrices (2014) (13)
- Serological response following BNT162b2 anti‐SARS‐CoV‐2 mRNA vaccination in haematopoietic stem cell transplantation patients (2021) (13)
- Superior Rate of Complete Response with up-Front Velcade-Thalidomide-Dexamethasone Versus Thalidomide-Dexamethasone in Newly Diagnosed Multiple Myeloma Is Not Affected by Adverse Prognostic Factors, Including High-Risk Cytogenetic Abnormalities. (2008) (13)
- Monitoring the dispersion process of SWNTs in aqueous solutions by UV-vis and Raman spectroscopies. (2009) (13)
- Peg-filgrastim versus filgrastim after autologous stem cell tranplantation: case-control study in patients with multiple myeloma and review of the literature. (2007) (13)
- Upfront Autologous Hematopoietic Stem-Cell Transplantation Improves Overall Survival in Comparison with Bortezomib-Based Intensification Therapy in Newly Diagnosed Multiple Myeloma: Long-Term Follow-up Analysis of the Randomized Phase 3 EMN02/HO95 Study (2020) (13)
- Pamidronate for early-stage, untreated myeloma. (2003) (13)
- Circulating Regulatory T-Cells in Monoclonal Gammopathies of Uncertain Significance and Multiple Myeloma: In Search of a Role (2016) (13)
- Sorption Thermodynamics of CO2, H2O, and CH3OH in a Glassy Polyetherimide: A Molecular Perspective (2019) (13)
- Proposal and Validation of Prognostic Scoring Systems for IgG and IgA Monoclonal Gammopathies of Undetermined Significance (2009) (13)
- Carfilzomib-based induction/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk patients. (2021) (12)
- Comparative analysis of azacitidine and intensive chemotherapy as front-line treatment of elderly patients with acute myeloid leukemia (2018) (12)
- The role of bisphosphonates for the treatment of bone disease in multiple myeloma. (1998) (12)
- Prognostic relevance of serum beta 2-microglobulin in acute myeloid leukemia. (1992) (12)
- Thermodynamics of water sorption in high performance glassy thermoplastic polymers (2014) (12)
- Impact of Bortezomib- or Lenalidomide-Based Induction Treatment on High Risk Cytogenetic Transplant-Ineligible Patients with Newly Diagnosed Multiple Myeloma Enrolled in the Gimema-MM-03-05 and EMN01 Trials (2017) (12)
- Continuous infusion idarubicin and intravenous busulphan as conditioning regimen to autologous stem cell transplantation for patients with acute myeloid leukaemia (2009) (12)
- Effects of sympathetic blockade on the efficiency of forced-air warming during combined spinal-epidural anesthesia for total hip arthroplasty. (1999) (12)
- Immunomodulatory Drugs in Acute Myeloid Leukemia Treatment (2020) (12)
- Final Results of a Phase II Study Evaluating Lenalidomide in Combination with Low Dose Dexamethasone As First Line Therapy for Primary Plasma Cell Leukemia (2011) (12)
- Bortezomib-Thalidomide-Dexamethasone Compared with Thalidomide-Dexamethasone as Induction and Consolidation Therapy Before and After Double Autologous Transplantation In Newly Diagnosed Multiple Myeloma: Results From a Randomized Phase 3 Study (2010) (12)
- Diffusion and molecular interactions in a methanol/polyimide system probed by coupling time-resolved FTIR spectroscopy with gravimetric measurements (2013) (12)
- Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin's lymphoma. (2017) (12)
- Dysregulation of miRNA in Leukemia: Exploiting miRNA Expression Profiles as Biomarkers (2021) (12)
- Modulation of CD20 antigen expression after rituximab treatment: a retrospective study in patients with chronic lymphocytic leukemia. (2010) (12)
- All-trans retinoic acid for advanced multiple myeloma. (1995) (12)
- A comparative analysis of biosimilar vs. originator filgrastim in combination with plerixafor for stem cell mobilization in lymphoma and multiple myeloma: a propensity‐score weighted multicenter approach (2017) (11)
- A reduced intensity conditioning regimen for allografting following autografting is feasible and has strong anti-myeloma activity. (2004) (11)
- Carfilzomib, cyclophosphamide and dexamethasone for newly diagnosed, high-risk myeloma patients not eligible for transplant: a pooled analysis of two studies (2020) (11)
- Optical switching property from a laser beam propagating in a polymer dispersed liquid crystal film (2001) (11)
- Life for patients with myelofibrosis: the physical, emotional and financial impact, collected using narrative medicine—Results from the Italian ‘Back to Life’ project (2018) (11)
- Multiparameter flow cytometry (MFC) and next generation sequencing (NGS) for minimal residual disease (MRD) evaluation: Results of the FORTE trial in newly diagnosed multiple myeloma (MM). (2020) (11)
- Second Primary Malignancies in Newly Diagnosed Multiple Myeloma Patients Treated with Lenalidomide: Analysis of Pooled Data in 2459 Patients (2011) (11)
- Secondary malignancies in elderly myeloma patients (2011) (11)
- DNA methylation dynamic of bone marrow hematopoietic stem cells after allogeneic transplantation (2019) (11)
- Plasticization mechanism in polybenzimidazole membranes for organic solvent nanofiltration: Molecular insights from in situ FTIR spectroscopy (2020) (11)
- Acute myeloid leukemia following 3M (mitoxantrone, mitomycin and methotrexate) chemotherapy for advanced breast cancer (1997) (11)
- CD79b expression in B-cell chronic lymphocytic leukemia. (2000) (11)
- EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells (2017) (11)
- Oxidative stress in chronic lymphocytic leukemia: still a matter of debate (2018) (11)
- Grand challenges in polymer chemistry: energy, environment, health (2013) (11)
- 2021 European Myeloma Network review and consensus statement on smoldering multiple myeloma: how to distinguish (and manage) Dr. Jekyll and Mr. Hyde (2021) (11)
- Italian real life experience with brentuximab vedotin: results of a large observational study on 234 relapsed/refractory Hodgkin’s lymphoma (2017) (11)
- Selective surface modification of syndiotactic polystyrene films: A study by Fourier transform- and confocal-Raman spectroscopy (2010) (10)
- Targeting regulatory T cells for anticancer therapy. (2011) (10)
- How to treat patients with relapsed/refractory multiple myeloma: evidence-based information and opinions (2011) (10)
- Poor Prognosis of Multiple Myeloma Predicted By High Levels of Circulating Plasma Cells Is Independent from Other High-Risk Features but Is Modulated By the Achievement of Minimal Residual Disease Negativity (2020) (10)
- Upgrading of unsaturated polyesters by reactive blending with bismaleimide resins (1996) (10)
- Iron Toxicity and Chelation Therapy in Hematopoietic Stem Cell Transplant. (2020) (10)
- Unbiased pro-thrombotic features at diagnosis in 977 thrombocythemic patients with Philadelphia-negative chronic myeloproliferative neoplasms. (2016) (10)
- Correlation between fatigue and hemoglobin level in multiple myeloma patients: results of a cross-sectional study. (2005) (10)
- Myelomatous nodular lesions of the liver: Diagnosis by ultrasound‐guided fine‐needle biopsy (1993) (10)
- Analysis of Amount, Size, Protein Phenotype and Molecular Content of Circulating Extracellular Vesicles Identifies New Biomarkers in Multiple Myeloma (2021) (10)
- A polymer network of unsaturated polyester and bismaleimide resins: Yielding and fracture behaviour (1996) (10)
- Triamcinolone solubilization by (2-hydroxypropyl)-β-cyclodextrin: A spectroscopic and computational approach. (2012) (10)
- The expression of the multidrug transporter P-170 glycoprotein in remission phase is associated with early and resistant relapse in multiple myeloma. (1991) (10)
- An analysis of which subgroups of multiple myeloma patients, divided according to b(2)-microglobulin and plasma cell labeling index, benefit from high dose vs conventional chemotherapy. (1999) (10)
- Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study (2017) (10)
- Symptomatic myopathy during interferon alfa therapy for chronic myelogenous leukemia (1998) (9)
- Chronic lymphocytic leukemia after chronic myeloid leukemia in the same patient: two different genomic events and a common treatment? (2012) (9)
- First-line treatment of multiple myeloma in elderly patients: the GIMEMA (Gruppo Italiano Malattie EMatologiche dell'Adulto) multiple myeloma working party perspective. (2009) (9)
- Bulk functionalization of ethylene-propylene copolymers. IV: A theoretical approach (1992) (9)
- Polyurethane synthesis under high-pressure CO2, a FT-NIR study (2019) (9)
- A Pyrazolo[3,4-d]pyrimidine Compound Reduces Cell Viability and Induces Apoptosis in Different Hematological Malignancies (2016) (9)
- Italian real-life experience with brentuximab vedotin: results of a large observational study of 40 cases of relapsed/refractory systemic anaplastic large cell lymphoma (2017) (9)
- Hypomethylating agents for the treatment of acute myeloid leukemia in the elderly (2011) (9)
- Surface endoglin (CD105) expression on acute leukemia blast cells: an extensive flow cytometry study of 1002 patients (2018) (9)
- High Levels of Circulating Tumor Plasma Cells as a Key Hallmark of Aggressive Disease in Transplant-Eligible Patients With Newly Diagnosed Multiple Myeloma (2022) (9)
- Raman Line Imaging of Poly(ε-caprolactone)/Carbon Dioxide Solutions at High Pressures: A Combined Experimental and Computational Study for Interpreting Intermolecular Interactions and Free-Volume Effects. (2016) (9)
- Crystallization from the amorphous form of the nanoporous ɛ form of syndiotactic polystyrene (2010) (9)
- Benzene-Induced Crystallization of PPO: A Combined Thermodynamic and Vibrational Spectroscopy Study (2020) (9)
- Oral Melphalan, Prednisone and Thalidomide for Multiple Myeloma. (2005) (9)
- Water Diffusion in Glassy Polymers and their Silica Hybrids: an Analysis of State of Water Molecules and of the Effect of Tensile Stress (2007) (9)
- Alliance Against Cancer, the network of Italian cancer centers bridging research and care (2015) (9)
- Oral RevlimidR Plus Melphalan and Prednisone (R-MP) for Newly Diagnosed Multiple Myeloma. (2005) (9)
- The role of recombinant erythropoietin for the treatment of anemia in multiple myeloma. (1998) (9)
- Effects of perfluoroether concentration and curing protocol on morphology and mechanical properties of toughened TGDDM/MNA resin systems (2003) (9)
- Treatment Intensification With Autologous Stem Cell Transplantation and Lenalidomide Maintenance Improves Survival Outcomes of Patients With Newly Diagnosed Multiple Myeloma in Complete Response (2018) (8)
- Impedance spectroscopy of highly cross-linked epoxy resin/bisphenol A-based polycarbonate (1999) (8)
- Oral melphalan, prednisone and thalidomide for newly diagnosed myeloma patients (2004) (8)
- Influence of addition of modified ethylene‐propene elastomer on the properties of poly(tetramethylene terephthalate)‐based blends (1988) (8)
- Fracture behaviour and deformation mechanisms of polyimide/silica hybrids (2005) (8)
- Younger patients with Waldenström Macroglobulinemia exhibit low risk profile and excellent outcomes in the era of immunotherapy and targeted therapies (2020) (8)
- Azacitidine for Post-Remission Therapy in Elderly Patients with Acute Myeloid Leukemia : Final Results of the Qoless AZA-Amle Randomized Trial (2019) (8)
- Spectroscopic, Mechanical and Dynamic-Mechanical Studies on the Photo-Aging of a Tetrafunctional Epoxy Resin (2009) (8)
- Real world Italian experience of pomalidomide plus low-dose dexamethasone in the relapsed and refractory myeloma setting: extended follow-up of a retrospective multicenter study by the ‘Rete Ematologica Pugliese E Basilicata’ (2019) (8)
- Serum levels of soluble calreticulin predict for time to first treatment in early chronic lymphocytic leukaemia (2016) (8)
- Continuous treatment (CT) versus fixed duration of therapy (FDT) in newly diagnosed myeloma patients: PFS1, PFS2, OS endpoints. (2014) (8)
- Effect of Morphology on the Relaxation Processes and Mechanical Properties in Polyimide/Silica Hybrids (2007) (8)
- Impact of Minimal Residual Disease (MRD) By Multiparameter Flow Cytometry (MFC) and Next-Generation Sequencing (NGS) on Outcome: Results of Newly Diagnosed Transplant-Eligible Multiple Myeloma (MM) Patients Enrolled in the Forte Trial (2020) (8)
- Circulating hematopoietic progenitor cells in leukapheresis: flow cytometric estimation. (1996) (8)
- Nanocomposite Fibers for Cosmetotextile Applications (2006) (8)
- Employment of Oligodeoxynucleotide plus Interleukin-2 Improves Cytogenetic Analysis in Splenic Marginal Zone Lymphoma (2011) (8)
- The clinical and biological role of CD20 membrane antigen modulation under immunotherapy with anti-CD20 monoclonal antibody rituximab in lymphoprolipherative neoplastic disorders (2011) (8)
- Time-resolved FTIR/FTNIR spectroscopy: powerful tools to investigate diffusion processes in polymeric films and membranes (2002) (8)
- Plasmonic octagonal quasicrystals for surface enhanced Raman sensing (2015) (8)
- Prospective validation of predictive value of abdominal computed tomography scan on time to first treatment in Rai 0 chronic lymphocytic leukemia patients: results of the multicenter O‐CLL1‐GISL study (2016) (8)
- Clofarabine: in search of combinations for the treatment of patients with high-risk acute myeloid leukemia. (2008) (8)
- Morphology, molecular interactions and H2O diffusion in a poly(lactic-acid)/graphene composite: A vibrational spectroscopy study. (2019) (8)
- 90Y-Ibritumomab Tiuxetan as Consolidation Therapy After Autologous Stem Cell Transplantation in Aggressive Non-Hodgkin Lymphoma (2011) (7)
- Direct printing of gold nanospheres from colloidal solutions by pyro-electrohydrodynamic jet allows hypersensitive SERS sensing (2020) (7)
- Features, reason for testing, and changes with time of 583 paroxysmal nocturnal hemoglobinuria clones from 529 patients: a multicenter Italian study (2019) (7)
- Water sorption thermodynamics in poly(propylene sebacate) (2016) (7)
- Oral Melphalan, Prednisone, and Lenalidomide for Newly Diagnosed Multiple Myeloma Patients: Kinetics of Neutropenia/Thrombocytopenia and Time to Event Results (2008) (7)
- Identification of three novel mutations in the PIG-A gene in paroxysmal nocturnal haemoglobinuria (PNH) patients (2004) (7)
- Maintenance in myeloma patients achieving complete response after upfront therapy: a pooled analysis (2018) (7)
- Drug Conjugated and Bispecific Antibodies for Multiple Myeloma: Improving Immunotherapies off the Shelf (2021) (7)
- Newly proposed therapy-related myelodysplastic syndrome prognostic score predicts significant differences in overall survival and leukemia-free survival in patients treated with azacitidine (2013) (7)
- Thymidine kinase in neoplastic haematological diseases: confirmations, doubts and new findings. (1988) (7)
- Long Term Outcome of Lenalidomide-Dexamethasone (Rd) Vs Melphalan-Lenalidomide-Prednisone (MPR) Vs Cyclophosphamide-Prednisone-Lenalidomide (CPR) As Induction Followed By Lenalidomide-Prednisone (RP) Vs Lenalidomide (R) As Maintenance in a Community-Based Newly Diagnosed Myeloma Population: Updated (2017) (7)
- Acute myeloid leukemia: correlation between FAB classification criteria and surface antigenic markers. (1988) (7)
- Misleading cytogenetic evidence of relapse in donor cells after allogeneic bone marrow transplantation corrected by fluorescent in situ hybridization. (1995) (7)
- Depth profiles in confocal optical microscopy: a simulation approach based on the second Rayleigh-Sommerfeld diffraction integral. (2016) (7)
- Effects of erythropoiesis-stimulating agents on overall survival of International Prognostic Scoring System Low/Intermediate-1 risk, transfusion-independent myelodysplastic syndrome patients: a cohort study (2018) (7)
- Water Sorption Thermodynamics and Mass Transport in Poly(ϵ-Caprolactone): Interactional Issues Emerging from Vibrational Spectroscopy (2013) (7)
- TREATMENT OF PLASMA CELL LEUKAEMIA AND RESISTANT/RELAPSED MULTIPLE MYELOMA WITH VINCRISTINE, MITOXANTRONE AND DEXAMETHASONE (VMD PROTOCOL) (1991) (7)
- 451 High prevalence of hepatitis B virus infection in b-cell non-hodgkin lymphoma (2006) (7)
- Structure-Properties Correlation in Polyimide/Silica Hybrids (2006) (7)
- Peg-Filgrastim after Autologous Peripheral Blood Stem Cell Transplantation in Hematological Malignancies. (2004) (7)
- SARS-CoV-2 in Myelodysplastic Syndromes: A Snapshot From Early Italian Experience (2020) (6)
- Acquired Hemophilia A Successfully Treated with Rituximab (2015) (6)
- Photonic bandgap influence on the SERS effect in metal-dielectric colloidal crystals optical fiber probe (2021) (6)
- Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study (2020) (6)
- Imatinib-mesylate for all patients with hypereosinophilic syndrome? (2004) (6)
- Correlation Between Clinical Outcome and Disease Kinetics by Quantitative PCR in Myeloma Patients Following Post-Transplant Consolidation with Bortezomib, Thalidomide and Dexamethasone. (2009) (6)
- Letermovir Prophylaxis for Cytomegalovirus Infection in Allogeneic Stem Cell Transplantation: A Real-World Experience (2021) (6)
- CD200 and prognosis in chronic lymphocytic leukemia: Conflicting results. (2019) (6)
- Ciculating CD34+ absolute cell number is the best single parameter to predict the quality of leukapheretic yield (1998) (6)
- Pyridine Controlled Tin Perovskite Crystallization (2022) (6)
- High Predictive Value of the Revised International Prognostic Scoring System (IPSS-R): An External Analysis of 646 Patients From a Multiregional Italian MDS Registry (2012) (6)
- Bendamustine in relapsed/refractory multiple myeloma: the “real-life” side of the moon (2015) (6)
- A phase II trial on alpha-interferon (alpha IFN) effect in patients with monoclonal IgM gammopathy. (1994) (6)
- Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRA Rearrangement Can Be Effectively Treated with Imatinib. (2004) (6)
- What Is New in the Treatment of Smoldering Multiple Myeloma? (2021) (6)
- “Residual” crystallinity and superreticular order in ethylene‐propylene rubbers prepared with different catalytic systems (1987) (6)
- Recombinant erythropoietin for refractory anemia with ring sideroblasts. (1992) (6)
- Fournier's gangrene complicating thrombocytopenia treated with steroids (2014) (6)
- Cardio-vascular Toxicity in Newly Diagnosed, Transplant-ineligible Multiple Myeloma Patients Treated With Carfilzomib, Cyclophosphamide and Dexamethasone: Results From an Integrated Analysis of 3 Phase I/II Trials (2017) (6)
- Alpha interferon in the treatment of chronic myelomonocytic leukemia. (1989) (6)
- A Real Life Evaluation of Efficacy and Safety of Ponatinib Therapy in CML Patients (2017) (6)
- Second primary malignancies (SPM) in newly diagnosed myeloma (MM) patients treated with lenalidomide (Len): Meta-analysis of 6,383 individual patient data (IPD). (2013) (5)
- Transcriptomic Analysis in Multiple Myeloma and Primary Plasma Cell Leukemia with t(11;14) Reveals Different Expression Patterns with Biological Implications in Venetoclax Sensitivity (2021) (5)
- Role of thalidomide in previously untreated patients with multiple myeloma (2008) (5)
- Increased CD10/TdT positive cells in the bone marrow of an infant with immune thrombocytopenia. (1994) (5)
- Plasma cell acid phosphatase in multiple myeloma. (1993) (5)
- Bortezomib, melphalan, prednisone, and thalidomide (VMPT) followed by maintenance with bortezomib and thalidomide (VT) for initial treatment of elderly multiple myeloma patients. (2010) (5)
- Normal G-CSF-mobilized CD34+ peripheral blood stem cells in paroxysmal nocturnal hemoglobinia: a perspective for autologous transplantation (1997) (5)
- Observational Study of CML Italian Patients Who Discontinued TKIs (2017) (5)
- Desferrioxamine improves burst-forming unit-erythroid (BFU-E) proliferation in haemodialysis patients. (1998) (5)
- Identification of High-Risk Multiple Myeloma With a Plasma Cell Leukemia-Like Transcriptomic Profile (2021) (5)
- Revisiting the use of recombinant erythropoietin in myelodysplastic syndromes. (2005) (5)
- Treatment of elderly patients with chronic lymphocytic leukemia: an unmet cinical need (2013) (5)
- A Randomized Study of Carfilzomib-Lenalidomide-Dexamethasone Vs Carfilzomib-Cyclophosphamide-Dexamethasone Induction in Newly Diagnosed Myeloma Patients Eligible for Transplant: High Efficacy in High- and Standard-Risk Patients (2017) (5)
- Management of infectious risk of daratumumab therapy in multiple myeloma: a consensus-based position paper from an ad hoc Italian expert panel. (2022) (5)
- Autologous stem cell transplantation (ASCT) vs ASCT followed by reduced-intensity conditioning allogeneic SCT with identical sibling donor in previously untreated multiple myeloma: preliminary analysis of a prospective controlled trial by the EBMT (2008) (5)
- Again about bone marrow necrosis: particular diagnostic aspects. (1989) (5)
- Low-dose thalidomide and dexamethasone improves survival in advanced multiple myeloma (2002) (5)
- Combination of Bortezomib, Melphalan, Prednisone and Thalidomide (VMPT) for Relapsed Multiple Myeloma: Results of a Phase I/II Clinical Trial. (2006) (5)
- Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells (2019) (5)
- Radioimmunotherapy ( 90 Y-Zevalin®) Combined with BEAM Conditioning Regimen and Autologous Stem Cell Transplantation for the Treatment of Non Hodgkin Lymphomas: Results of An Italian Multicenter Study. (2008) (5)
- Monoclonal B-cell lymphocytosis and prostate cancer: incidence and effects of radiotherapy (2019) (5)
- Myeloma cells regulate miRNA transfer from fibroblast‐derived exosomes by expression of lncRNAs (2021) (5)
- S872 CARFILZOMIB LENALIDOMIDE DEXAMETHASONE (KRD) WITH OR WITHOUT TRANSPLANTATION IN NEWLY DIAGNOSED MYELOMA (FORTE TRIAL): EFFICACY ACCORDING TO RISK STATUS (2019) (5)
- A Molecular Interpretation of the Dynamics of Diffusive Mass Transport of Water within a Glassy Polyetherimide (2021) (5)
- Oral melphalan, prednisone and thalidomide for newly diagnosed myeloma patients. (2004) (5)
- Synergistic effect of desferrioxamine and recombinant erythropoietin on erythroid precursor proliferation in chronic renal failure. (1999) (5)
- Doublet Vs Triplet Lenalidomide-Containing Regimens in Newly Diagnosed Myeloma Patients, Younger or Older Than 75 Years: Subgroup Analysis of a Phase III Study (2014) (5)
- From Biology to Clinical Practice: Iron Chelation Therapy With Deferasirox (2021) (5)
- Safety and Efficacy of Bendamustine with or without Rituximab for the Treatment of Heavily Pretreated CLL and Lymphoma Patients. A Multicenter Retrospective Study. (2009) (4)
- Bortezomib-Containing Combinations as Front-Line Therapy in Primary Plasma Cell Leukemia: A Retrospective Study From Gimema Multiple Myeloma and Acute Leukemia Working Parties (2010) (4)
- Accreditation for excellence of cancer research institutes: recommendations from the Italian Network of Comprehensive Cancer Centers. (2013) (4)
- Monoclonal antibodies in newly diagnosed and smoldering multiple myeloma: an updated review of current clinical evidence (2020) (4)
- [An unusual case of postoperative mechanical obstruction of the upper respiratory tract in a child]. (1977) (4)
- CFU—GM are not increased in peripheral blood of patients with chronic lymphocytic leukaemia (1996) (4)
- RECOMBINANT ERYTHROPOIETIN FOR MYELODYSPLASTIC SYNDROMES (1995) (4)
- Bortezomib (BOR)-Thalidomide-Dexamethasone (VTD) and High-Dose Melphalan (HDM) As First Line Treatment for Multiple Myeloma (MM) Is Associated with a Lower Rate of Second Primary Malignancies (SPMs) Compared to TD Plus HDM (2014) (4)
- Design and application of a novel PNA probe for the detection at single cell level of JAK2V617F mutation in Myeloproliferative Neoplasms (2013) (4)
- Significance and limits of cerebrospinal fluid beta‐2‐microglobulin measurement in course of acute lymphoblastic leukemia (1988) (4)
- Granulocyte colony-stimulating factor and erythropoietin for the anemia of myelodysplastic syndromes: a real improvement with respect to erythropoietin alone? (1994) (4)
- Pulmonary fat embolism in the traumatised patient: development of a prophylactic programme in a city accident hospital. (1975) (4)
- Nodular Lesions of the Liver in Multiple Myeloma: A Role for Cytoadhesion Molecules? (1992) (4)
- An Urologic Face of Chronic Lymphocytic Leukemia: Sequential Prostatic and Penis Localization (2013) (4)
- What is better for older patients with acute myeloid leukemia? (2013) (4)
- When to perform peripheral blood progenitor cell collection in hematological patients? (1997) (4)
- Toughened thermosetting bismaleimides: Molecular structure, morphology and mechanical properties (1997) (4)
- Recombinant Erythropoietin and Survival in Myelodysplastic Syndromes. (2005) (4)
- Reversible effects in IR absorption peaks of SiC:H, measured as a function of the temperature (2002) (4)
- Integrative Analysis of Baseline Prognostic Features and Achievement of Minimal Residual Disease Negativity As Predictors of Early Relapse in Transplant-Eligible Multiple Myeloma Patients (2019) (4)
- Minimal Residual Disease Monitoring During Maintenance In Multiple Myeloma Patients (2013) (4)
- Effect of cyclosporin-A on anemia in idiopathic myelofibrosis. (1998) (4)
- IRF4 expression is low in Philadelphia negative myeloproliferative neoplasms and is associated with a worse prognosis (2021) (4)
- External Validation On Biological Basis of New Prognostic Index in Early Asymptomatic Chronic Lymphocytic Leukemia (CLL) Patients: The Gruppo Italiano Studio Linfomi (GISL) Experience (2009) (4)
- Superiority of Droplet Digital PCR Over Real-Time Quantitative PCR for JAK2 V617F Allele Mutational Burden Assessment in Myeloproliferative Neoplasms: A Retrospective Study (2020) (4)
- Factor XI deficiency: two novel mutations in asymptomatic Italian patients (2010) (4)
- In Situ FT‐IR Spectroscopy Investigation of the Water Sorption of Amphiphilic PDMS Crosslinked Networks (2017) (4)
- FISH analysis reveals frequent co-occurrence of 4q24/TET2 and 5q and/or 7q deletions. (2012) (4)
- Combining FTIR spectroscopy and pressure-decay techniques to analyze sorption isotherms and sorption kinetics of pure gases and their mixtures in polymers: The case of CO2 and CH4 sorption in polydimethylsiloxane (2022) (4)
- Adjusted comparison between elotuzumab and carfilzomib in combination with lenalidomide and dexamethasone as salvage therapy for multiple myeloma patients (2021) (3)
- Proliferative activity in non-Hodgkin's lymphomas and chronic lymphocytic leukemias as determined on cytological samples by Ki 67 monoclonal antibody. (1990) (3)
- Is re-challenge still an option as salvage therapy in multiple myeloma? The case of REal-life BOrtezomib re-Use as secoND treatment for relapsed patients exposed frontline to bortezomib-based therapies (the REBOUND Study) (2018) (3)
- Advances in Azorella glabra Wedd. Extract Research: In Vitro Antioxidant Activity, Antiproliferative Effects on Acute Myeloid Leukemia Cells and Bioactive Compound Characterization (2020) (3)
- Neutralizing monoclonal antibodies in haematological patients paucisymptomatic for COVID‐19: The GIMEMA EMATO‐0321 study (2022) (3)
- Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) For The Treatment Of Patients With Relapsed Multiple Myeloma Confirms Very Promising Results In a Phase I/II Study (2013) (3)
- Antibody response to BNT162b2 SARS-CoV-2 mRNA vaccine is not influenced by AB0 blood group in subjects with transfusion-dependent thalassemia (2022) (3)
- Cell of origin (COO), BCL2/MYC status and IPI define a group of patients with Diffuse Large B-cell Lymphoma (DLBCL) with poor prognosis in a real-world clinical setting. (2021) (3)
- Clinical categories identified by a new prognostic index reflect biological characteristics of patients in early chronic lymphocytic leukemia: The Gruppo Italiano Studio Linfomi (GISL) experience. (2010) (3)
- Impact of Imaging FDG-PET/CT Minimal Residual Disease Assessment on Outcomes and Matching with Bone Marrow Techniques in Newly Diagnosed Transplant Eligible Multiple Myeloma (MM) Patients: Results of the Phase II Randomized Forte Trial (2020) (3)
- Plasma cell acid phosphatase in multiple myeloma [letter; comment] (1993) (3)
- 5-Azacytidine for the Treatment of Acute Myeloid Leukemia: A Retrospective, Multicenter Study of 55 Patients. (2008) (3)
- FLT3 mutational analysis in acute myeloid leukemia: Advantages and pitfalls with different approaches. (2022) (3)
- Dissecting chronic lymphocytic leukemia with 13q- using microRNA expression profile: Editorial for the paper "MiRNA expression profile of chronic lymphocytic leukemia patients with 13q deletion". (2016) (3)
- A Hyphenated Approach Combining Pressure-Decay and In Situ FT-NIR Spectroscopy to Monitor Penetrant Sorption and Concurrent Swelling in Polymers (2021) (3)
- Is the scoring system an effective clinico-biological tool in myeloid antigen positive adult acute lymphoblastic leukemia? Results of a long-term study. (2002) (3)
- Hypermethylation Is A Key Feature of the Transition of Multiple Myeloma to Plasma Cell Leukemia (2010) (3)
- Recycling of Polypropylene Based Car Bumpers: Mechanical and Morphological Analysis (2003) (3)
- Nanopore sequencing sheds a light on the FLT3 gene mutations complexity in acute promyelocytic leukemia (2020) (3)
- Carfilzomib combined with lenalidomide and dexamethasone (KRd) as salvage therapy for multiple myeloma patients: italian, multicenter, retrospective clinical experience with 600 cases outside of controlled clinical trials (2022) (3)
- [Perioperative thermal homeostasis. A duty of the anesthesiologist]. (1997) (3)
- Hereditary myeloperoxidase deficiency syndrome. Clinical and haematological data of ten cases (1985) (3)
- P116 Azacitidine for the treatment of lower risk myelodysplastic syndromes: final results from an Italian named patient program (2009) (3)
- Development and characterization of porous membranes with “sandwich-like” structure based on biocompatible, immiscible polymer blends (2007) (3)
- Structural feature of thermo-induced fluorochromism in a 1D zinc coordination polymer. A cross-analysis by PL and FTIR spectroscopy, and DFT formalism (2022) (3)
- Clinical usefulness of immunocytochemical detection of myeloperoxidase in undifferentiated and biphenotypic acute leukemias. (1991) (3)
- Low-Dose Dasatinib as Front-Line Therapy for Elderly (> 60 Years) Patients with CML (2010) (3)
- [Striated muscle fibers and CI-581]. (1969) (3)
- Elotuzumab plus lenalidomide and dexamethasone in relapsed/refractory multiple myeloma: Extended 3‐year follow‐up of a multicenter, retrospective clinical experience with 319 cases outside of controlled clinical trials (2022) (3)
- Monoclonal Antibodies and Multiple Myeloma: All in All It's Just Another Brick in the Wall? (2018) (3)
- Treatment of Relapsed/Refractory Waldenström Macroglobulinemia Patients: Final Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) (2021) (3)
- Octogenarian newly diagnosed multiple myeloma patients without geriatric impairments: the role of age >80 in the IMWG frailty score (2021) (3)
- Reply to the article 'Hepatitis C virus (HCV) infection and MALT-type ocular adnexal lymphoma (OAL)' by P. Arnaud, M.-C. Escande, M. Lecuit et al. (Ann Oncol doi:10.1093/annonc/mdl369). (2006) (3)
- The Role of Autoimmune Diseases in the Prognosis of Lymphoma (2020) (3)
- Selected case from the Arkadi M. Rywlin international pathology slide series: lymphangiomatosis of the spleen associated with ipsilateral abdominopelvic and lower extremity venolymphatic malformations: a case report and review of the literature. (2014) (3)
- Role of FDG-PET As Prognostic Indicator in Patients with Follicular Lymphoma(FL) After Immunochemotherapy Induction. A Retrospective Study From the Fondazione Italiana Linfomi (2011) (3)
- Tumor Circulating Plasma Cells Detected By Flow Cytometric Single Platform Method Correlate with Clinical Response to Therapy and Unfavorable Patients' Characteristics (2019) (3)
- Heavy/light chain ratio for the assessment of minimal residual disease in myeloma patients achieving complete response (2018) (3)
- Epitranscriptomics in Normal and Malignant Hematopoiesis (2020) (3)
- Clonal Hematopoiesis at the Crossroads of Inflammatory Bowel Diseases and Hematological Malignancies: A Biological Link? (2022) (3)
- Prognostic Factors for Overall Survival In Chronic Myeloid Leukemia Patients: A Multicentric Cohort Study by the Italian CML GIMEMA Network (2021) (3)
- Effects of different doses of erythropoietin in patients with myelodysplastic syndromes: A propensity score‐matched analysis (2019) (3)
- Nanopore sequencing approach for immunoglobulin gene analysis in chronic lymphocytic leukemia (2021) (3)
- Circulating Mir-16 and Mir-25 As New Prognosticators For Multiple Myeloma (2013) (3)
- Development and Validation of a Simplified Score to Predict Early Relapse in Newly Diagnosed Multiple Myeloma in a Pooled Dataset of 2,190 Patients (2021) (3)
- Car fi lzomib , cyclophosphamide , and dexamethasone in patients with newly diagnosed multiple myeloma : a multicenter , phase 2 study (2014) (3)
- Hepatitis C Virus and B-cell non-Hodgkin Lymphomas: An Italian multi-centre case-control study (2003) (3)
- Cytofluorimetric and immunohistochemical comparison for detecting bone marrow infiltration in non-Hodgkin lymphomas: a study of 354 patients. (2019) (3)
- Oriented Nanoporous Host δ Phases of Syndiotactic Polystyrene as a Tool for Spectroscopic Investigation of Guest Molecules (2006) (3)
- Final Analysis of a Multicenter, Randomised Study Comparing Zoledronate vs Observation in Patients with Asymptomatic Myeloma. (2007) (3)
- Cytogenetic and Molecular Responses At 3 Months Are Associated with A Better Outcome in Early Chronic Phase (ECP) Chronic Myeloid Leukemia (CML) Patients Treated with Nilotinib. (2012) (3)
- A case of acute promyelocytic leukemia variant with derivative chromosome 3 der(3)t(3;8) associated with 8q partial gain (2019) (2)
- Clinical and Molecular Results of the Phase II Brb (Bendamustine, Rituximab and Bortezomib) Trial of the Fondazione Italiana Linfomi (FIL) for Relapsed/Refractory Waldenström Macroglobulinemia Patients (2018) (2)
- Second Cancer Onset in Myeloproliferative Neoplasms: What, When, Why? (2022) (2)
- SARS-CoV-2 infection in fully vaccinated patients with multiple myeloma (2021) (2)
- Impact of severe acute respiratory syndrome coronavirus‐2 infection on the outcome of primary central nervous system lymphoma treatment: A study of the International PCNSL Collaborative Group (2022) (2)
- Final Results Of a Phase II Study Of Lenalidomide In Combination With Rituximab For The Treatment Of Indolent Non Follicular Non Hodgkin Lymphoma (2012) (2)
- Isotactic polypropylene: an attempt to correlate crystallization conditions, superreticular structure, and impact properties (1988) (2)
- Use of protein pathway activation mapping of NSCLC to identify distinct molecular subtypes and a prognostic signature for aggressive node-negative tumors. (2010) (2)
- Primary Plasma Cell Leukemia: Results of a Retrospective Italian Multicentric Survey. (2009) (2)
- Pamidronate for early-stage, untreated myeloma. Authors' reply (2003) (2)
- Lenalidomide (LEN) Maintenance Following High-Dose Melphalan and Autologous Stem Cell Transplant (ASCT) in Patients (Pts) With Newly Diagnosed Multiple Myeloma (MM): A Meta-Analysis of Overall Survival (OS) (2017) (2)
- Different spatial distribution of inflammatory cells in the tumor microenvironment of ABC and GBC subgroups of diffuse large B cell lymphoma (2021) (2)
- The Use of FDG-PET in the Initial Staging of Patients with Follicular Lymphoma (FL). A Retrospective Study From the Fondazione Italiana Linfomi (2011) (2)
- Front-Line Chemo-Immunotherapy Rituximab-FC + Rituximab Maintenance in Patients with Untreated Advanced Stage Non Follicular Lymphoma (INFL): Preliminary Results of a Prospective Study of the Intergruppo Italiano Linfomi and Roche (ML18324). (2008) (2)
- Azacitidine in Older Patients with Acute Myeloid Leukemia (AML). Results from the Expanded International E-Alma Series (E-ALMA+) According to the MRC Risk Index Score (2015) (2)
- Tandem bone marrow transplantation in multiple myeloma. (2004) (2)
- Serological response following anti-SARS-CoV-2 vaccination in hematopoietic stem cell transplantation patients depends upon time from transplant, type of transplant and “booster”dose (2022) (2)
- Thalidomide-induced psoriasis in a patient with multiple myeloma (2019) (2)
- In Multiple Myeloma, Minimal Residual Disease (MRD) Is an Early Predictor of Progression and Is Modulated By Maintenance Therapy with Lenalidomide (2014) (2)
- RUNX1 gene alterations characterized by allelic preference in adult acute myeloid leukemia (2021) (2)
- Bortezomib and Plasma Cell Leukemia. (2006) (2)
- PCR-Based Minimal Residual Disease (MRD) Detection Is a Strong Independent Outcome Predictor Also in Rituximab-Intensive Non-ASCT-Based Programs: Results From the ML17638 Multicenter Randomised Phase III Trial for Elderly Follicular Lymphoma (FL) Patients of the Fondazione Italiana Linfomi (FIL) (2012) (2)
- A PROSPECTIVE RANDOMIZED TRIAL OF BORTEZOMIB-MELPHALANPREDNISONE-THALIDOMIDE FOLLOWED BY CONTINUOUS BORTEZOMIB-THALIDOMIDE FOR INITIAL THERAPY OF MULTIPLE MYELOMA:EFFECT OF AGE AND CO-MORBIDITIES (2010) (2)
- Graphene oxide-based nanohybrid for label-free optical sensing (2014) (2)
- “Hemolysis, or not Hemolysis, that is the Question”. Use of Hydroxychloroquine in a Patient with COVID-19 Infection and G6PD Deficiency (2020) (2)
- Bortezomib (VEL) Based Regimens in Multiple Myeloma (MM) Patients with Renal Impairment (RI): A Preliminary Retrospective Italian Multicenter Study (2008) (2)
- The impact of graft CD3/Tregs ratio on aGvHD and post-transplant outcome: a prospective multicenter study on patients with acute leukemia undergoing allogeneic peripheral blood stem cell transplantation. (2021) (2)
- The Effect of the Tumor Microenvironment on Lymphoid Neoplasms Derived from B Cells (2022) (2)
- Incidence and outcome of SARS-CoV-2 infection in patients with monoclonal gammopathy of undetermined significance: a case-control study (2021) (2)
- A Phase I/II Study of Bendamustine, Low-Dose Dexamethasone, and Lenalidomide (BdL) for the Treatment of Patients with Relapsed Multiple Myeloma (2012) (2)
- Overall survival of myelodysplastic syndrome patients after azacitidine discontinuation and applicability of the North American MDS Consortium scoring system in clinical practice (2021) (2)
- Lenalidomide differently modulates CD20 antigen surface expression on chronic lymphocytic leukemia B-cells (2015) (2)
- Use of protein pathway mapping of brain metastasis from breast and lung cancer patients to identify new therapeutic targets: A seed/soil study. (2010) (2)
- Prognostic models to predict survival in indolent and aggressive non-Hodgkin’s lymphomas associated with hepatitis C virus infection: A multicenter Italian study on 1,043 patients (2010) (2)
- Age Influences Initial Dose and Compliance to Imatinib In Chronic Myeloid Leukemia Elederly Patients but Concomitant Comorbidities Appear to Influence Overall and Event-Free Survival (2011) (2)
- Novel Agents for the Treatment of Primary Plasma-Cell Leukemia: Lights and Shadows (2015) (2)
- Outcome of Patients with CML Treated with Dasatinib or Nilotinib after Failure of Second Prior TKIs (2010) (2)
- Cytochemically unreactive neutrophils from subjects with myeloperoxidase (MPO) deficiency show a complex pattern of immunoreactivity with anti-MPO monoclonal antibodies: A flow cytometric and immunocytochemical study (1991) (2)
- ACHIEVEMENT OF COMPLETE REMISSION IS A STRONG PROGNOSTIC FACTOR IN 895 ELDERLY MYELOMA PATIENTS TREATED WITH MELPHALAN-PREDNISONE BASED-REGIMENS: RESULTS OF 3 MULTICENTER ITALIAN TRIALS (2010) (2)
- Updated efficacy data and MRD analysis according to risk status in newly diagnosed myeloma patients treated with carfilzomib + lenalidomide or cyclophosphamide (FORTE trial). (2018) (2)
- Exposure of Cord Blood Hematopoietic Stem Cells to Bone Marrow Mesenchimal Cells-Derived Microvesicles Induces Cell Survival and Inhibition of Differentiation (2014) (2)
- Clonal hematopoiesis in clinical practice: walking a tightrope (2022) (2)
- Genomics of Smoldering Multiple Myeloma: Time for Clinical Translation of Findings? (2021) (2)
- Metallic-Dielectric colloidal photonic crystal on the multimode optical fiber tip: preliminary results as optical fiber SERS probe (2019) (2)
- Azacitidine As Post-Remission Therapy in Elderly Patients with Acute Myeloid Leukemia Significantly Prolongs Disease-Free Survival: Interim Results from a Prospective, Randomized, Open-Label, Phase III Multicenter Trial (2014) (2)
- Bortezomib as Front-Line Therapy in Primary Plasma Cell Leukemia (2008) (2)
- JAK2 V617f in chronic myeloid leukemia: driving force or passive bystander? (2022) (2)
- Prognostic Models to Predict Survival In Indolent and Aggressive Non-Hodgkin's Lymphomas Associated with Hepatitis C Virus Infection: a Multicenter Italian Study on 1,043 Patients. (2010) (2)
- The investigation of genomic profiles in plasma cell leukemias by means of an integrative microarray approach (2011) (2)
- Bendamustine As Salvage Therapy in Multiple Myeloma: A Retrospective, Multicenter Study From the Italian Compassionate Use Program in 78 Heavily Pre-Treated Patients. (2012) (2)
- Nodal aggressive non-Hodgkin’s lymphoma in the adult: a review article (2005) (2)
- Modification of QRS pattern in a patient with AL amyloidosis. (2013) (2)
- Achievement of European Standards by CROB-IRCCS (2015) (2)
- Investigation of the CO2 Adsorption on Cubtc by Combining Vibrational Spectroscopy and Molecular Dynamics (2017) (2)
- Can the New and Old Drugs Exert an Immunomodulatory Effect in Acute Myeloid Leukemia? (2021) (2)
- Optical fiber SERS probe achieved by colloidal photonic crystal and gold nano-particles (2019) (2)
- Absolute monocyte count at diagnosis could improve the prognostic role of early FDG‐PET in classical Hodgkin lymphoma patients (2016) (2)
- [Acute lymphoblastic leukemia L3 in Hodgkin's disease in remission: primary or secondary leukosis?]. (1985) (2)
- Secondary infections worsen the outcome of COVID‐19 in patients with hematological malignancies: A report from the ITA‐HEMA‐COV (2022) (2)
- Novel Approaches Outside the Setting of Immunotherapy for the Treatment of Multiple Myeloma: The Case of Melflufen, Venetoclax, and Selinexor (2021) (1)
- Exploring the Potential of Eltrombopag: Room for More? (2022) (1)
- Iron Chelation Therapy with Deferasirox In Transfusion Dependent Myelodysplastic Syndrome Patients. Preliminary Report From the Prospective MDS0306 GIMEMA Trial (2010) (1)
- Meningeal Involvement in Primary Plasma Cell Leukemia (2018) (1)
- Indolent Lymphoproliferative T-Cell Disorders Associated With Gastrointestional Disease: Diagnostic Challenges and Outcomes. (2022) (1)
- INTERMEDIATE-DOSE MELPHALAN (100MG/M2), THALIDOMIDE, DEXAMETHASONE AND STEM CELL SUPPORT IN PATIENTS WITH REFRACTORY OR RELAPSED MYELOMA (2006) (1)
- Inside the biology of early T-cell precursor acute lymphoblastic leukemia: the perfect trick (2021) (1)
- Liquid crystals dispersed in thermosetting polymer matrices: molecular, morphological, and thermo-optical analysis (1997) (1)
- 5-Azacytidine in 82 Low/Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Results from the Italian Patient Named Program (2008) (1)
- Integrative Genomic Analysis of Primary Plasma Cell Leukemia Revealed Strong Gene and MicroRNA Dosage Effect (2010) (1)
- On the Mechanism of Mass Transport of Low Molecular Weight Compounds in Polyimides: Modeling and 2D-FTIR Analysis (2008) (1)
- Lenalidomide and Low Dose Dexamethasone As First Line Therapy for Newly Diagnosed Patients with Primary Plasma Cell Leukemia (2012) (1)
- IRF4 Gene Expression on the Trail of Molecular Response: Looking at Chronic Myeloid Leukemia from Another Perspective (2022) (1)
- Combining Plasma Cell Leukemia-like Status with the Second Revision of the International Staging System Improves Risk Classification (2022) (1)
- Erratum: Recombinant erythropoietin for myelodysplastic syndromes (British Journal of Haematology, 91, 256-257, (1995)) (1995) (1)
- COVID-19 in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS): An Observational Retrospective Study (2021) (1)
- Drug-related side effects after rituximab infusion in patients with chronic lymphocytic leukemia (2015) (1)
- 3D mapping of the output laser beam from a PDLC sample (2000) (1)
- program outcome in follicular lymphomas treated with a rituximab-intensive Persistence of minimal residual disease in bone marrow predicts (2013) (1)
- Spectroscopic Studies of the Diffusion of Water and Ammonia in Polyimide and Polyimide-Silica Hybrids (2005) (1)
- EFFICACY AND SAFETY PROFILE OF DASATINIB IN A SUBSET OF VERY ELDERLY PATIENS WITH CHRONIC MYELOID LEUKEMIA (CML) RESISTANT/INTOLERANT TO IMATINIB (2010) (1)
- P134 Recombinant erythropoietin for transfusion-dependent myelodysplastic syndromes: long-term follow-up shows no modification of the natural history of treated patients and suggests a possible better prognosis for responders (2007) (1)
- A RANDOMIZED PHASE II STUDY (GISL-MM03 TRIAL) WITH ORAL MELPHALAN plus PREDNISONE (MP) VERSUS MELPHALAN, plus PREDNISONE plus THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA (2009) (1)
- Imatinib In Very Elderly CML Patients: What Can We Achieve?. (2010) (1)
- An Integrated Analysis of Cardio-Vascular Adverse Events of Carfilzomib, Cyclophosphamide and Dexamethasone in Elderly Newly Diagnosed Myeloma Patients Enrolled in 3 Phase I/II Trials (2016) (1)
- OAB-011: Predictors of unsustained negativity in minimal residual disease (MRD)-negative transplant-eligible newly diagnosed multiple myeloma (MM) patients enrolled in the FORTE trial (2022) (1)
- Serological Response Following BNT162b2 Anti-Sars-Cov-2 mRNA Vaccination in Hematopoietic Stem Cell Transplantation Patients (2021) (1)
- Multi-sensing meta nanostructures with surface-enhanced Raman scattering and surface plasmon resonance functionalities (2017) (1)
- growth factor, in Hodgkin disease Expression of the c-met proto-oncogene and its ligand, hepatocyte (2013) (1)
- Clonal hematopoiesis onset in chronic myeloid leukemia patients developing an adverse cardiovascular event. (2023) (1)
- Vibrational Spectra of Poly(ethylene terephthalate) Chains in the Mesomorphic Form (2018) (1)
- A Pilot Study of Lenalidomide and Dexamethasone as First Line Therapy in Patients with Primary Plasma Cell Leukemia. (2009) (1)
- [Cardiac toxicity of modern local anesthetics. Electrocardiographic study]. (1969) (1)
- Treatment of Primary Plasma Cell Leukemia with Carfilzomib and Lenalidomide-Based Therapy: Results of the Final Analysis of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged 18-65 Years (2022) (1)
- Chapter 3 Thermosetting polyimides (1996) (1)
- Weak Interactions between Poly(ether imide) and Carbon Dioxide: A Multiscale Investigation Combining Experiments, Theory, and Simulations (2022) (1)
- Autografting Followed Closely by Nonmyeloablative Allografting as Consolidation Immunotherapy Reduces Disease Progression Compared to Tandem Autografting in Multiple Myeloma. (2005) (1)
- Bortezomib- and Thalidomide-Induced Peripheral Neuropathy (PN) in Multiple Myeloma (MM): Clinical and Molecular Analysis of 474 Patients Treated with Thalidomide-Dexamethasone (TD) or Bortezomib-TD (VTD) (2011) (1)
- The Role of Molecular Interactions in Controlling Methanol Diffusion in Polyimides: A Time‐Resolved FTIR Spectroscopy Investigation (2016) (1)
- Cerebro-spinal fluid thymidine kinase in acute leukemia. (1989) (1)
- Long-Term Follow-Up of Elderly Patients with Acute Myeloid Leukemia Treated with Decitabine: A Real-World Study of the Apulian Hematological Network (2022) (1)
- Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Anaplastic Large Cell Lymphoma (2016) (1)
- PHOTO‐AGING OF HIGH PERFORMANCE EPOXIES: SPECTROSCOPIC, MECHANICAL AND DYNAMIC‐MECHANICAL INVESTIGATIONS (2008) (1)
- Carfilzomib and Lenalidomide for the Treatment of Primary Plasma Cell Leukemia: Final Results of the Prospective Phase 2 EMN12/HOVON-129 Study for Patients Aged ≥66 Years (2022) (1)
- BENDAMUSTINE (B) IN COMBINATION WITH RITUXIMAB (R) FOR PATIENTS WITH RELAPSED/RESISTANT CHRONIC LYMPHOCYTIC LEUKEMIA (CLL): AN ITALIAN MULTICENTRE RETROSPECTIVE STUDY (2010) (1)
- [2 cases of anaphylactoid reaction caused by dextrans]. (1977) (1)
- Evolution of monoclonal antibodies in multiple myeloma. (2018) (1)
- Overall and complication‐free survival in a large cohort of patients with β‐thalassemia major followed over 50 years (2023) (1)
- OAB-055: Gain and amplification of 1q induce transcriptome deregulation and worsen the outcome of newly diagnosed Multiple Myeloma patients (2021) (1)
- Darbepoetin 500 mcg Q3W, Alone or in Combination with Peg-Filgrastim, in Low/Int1 IPSS Risk Myelodysplastic Syndromes Unresponsive to Recombinant Erythropoietin. (2007) (1)
- Phase II Study of Velcade® Plus Mabthera® In Relapsed Follicular Lymphomas (2010) (1)
- Revised-international staging system (R-ISS): A new and simple prognostic assessment for multiple myeloma (2014) (1)
- [Considerations on the theoretical and practical possibilities of modifying the pharmacodynamics of various drugs]. (1968) (1)
- Increased risk of neurological relapse in acute lymphoblastic leukemias with high levels of cerebrospinal fluid thymidine kinase at diagnosis. (1993) (1)
- CARFILZOMIB, CYCLOPHOSPHAMIDE AND DEXAMETHASONE (KCYD) IN ELDERLY NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM) PATIENTS: INITIAL RESULTS OF A PHASE 1 STUDY (2016) (1)
- Diffuse Large B Cell Lymphoma Arising in Patients with Preexisting Hodgkin Lymphoma (2022) (1)
- Melphalan 200 Mg/m 2 (Mel200) Versus Melphalan 100 Mg/m 2 (Mel100) in Newly Diagnosed Myeloma Patients: A Prospective, Randomized Phase III Study (2008) (1)
- Combination of Rituximab, Bortezomib and Hyper-Fractionated Cyclophosphamide (RBC) in “True” Elderly Patients with Advanced Mantle Cell Lympoma. (2007) (1)
- A Real Life Survey On Erythropoietin Alpha Treatment In a Cohort Of 1049 Low Risk MDS Patients: An Italian MDS Registry Study (2013) (1)
- EphA3 As a Molecular Target In Multiple Myeloma: Opportunity For a Novel Therapeutic Approach With a Specific Monoclonal Antibody (2013) (1)
- Inverse regulation of bridging integrator 1 and BCR-ABL1 in chronic myeloid leukemia (2015) (1)
- Belantamab Mafodotin in Patients with Relapsed and Refractory Multiple Myeloma Who Have Received at Least One Proteasome Inhibitor, One Immunomodulatory Agent and One Anti-CD38 Monoclonal Antibody: A Retro-Prospective Italian Observational Study (2022) (1)
- Tumor Cell Microenvironment and Microvessel Density Analysis in MALT Type Lymphoma (2021) (1)
- More on spontaneous regression of chronic lymphocytic leukemia: two new cases and potential role of lamivudine in a further patient with advanced disease and hepatitis B virus infection (2014) (1)
- Analysis of Transcriptome, Mirnome and Genomic Profiles in Association with Clinical Outcome in a Prospective Series of Primary Plasma Cell Leukemia (2012) (1)
- 87 Effects of three new recombinant. Human GM-CSF/Erythropoietin (EPO) hybrid molecules on in vitro growth of hemopoietic progenitors in myelodysplastic syndromes (MDS) (1997) (1)
- Venetoclax-Rituximab Treatment of Relapsed/Refractory CLL During the COVID-19 Pandemic: A Real-Life Experience in Selected Central-Southern Italian Regions (2021) (1)
- The Role of NLRP3, a Star of Excellence in Myeloproliferative Neoplasms (2023) (1)
- Plasma cell acid phosphatase and prognosis in multiple myeloma. (1994) (1)
- Effect of alpha IFN on unaggressive immunoproliferative disorders. (1995) (1)
- Thermo-Induced Fluorochromism in Two AIE Zinc Complexes: A Deep Insight into the Structure-Property Relationship (2022) (1)
- Lenalidomide Exhibits Activity in Mantle Cell Lymphoma through Increased NK Cell Mediated Cytotoxicity (2015) (1)
- Prognostic factors and high dose chemotherapy (1998) (1)
- Real‐life efficacy and safety of idelalisib in 55 double‐refractory follicular lymphoma patients (2022) (1)
- P141 High dose darbepoetin Q3W, alone or in combination with peg-filgrastim, for myelodysplastic syndromes unresponsive to recombinant erythropoietin (2007) (1)
- CPX-351 Induction in Secondary Acute Myeloblastic Leukemia: Extended Follow up from the Italian Compassionate Use Program (2021) (1)
- 192 Response to 5-azacytidine in therapy-related malignant neoplasms (t-MN) (2011) (1)
- Synthesis and Characterization of Interfacial Agents to be used in Polyamide 6/Rubber Blends (1984) (1)
- OAB-004: Carfilzomib-based induction/consolidation with or without autologous transplant and Lenalidomide (R) or Carfilzomib-Lenalidomide (KR) maintenance: efficacy in high-risk patients of the FORTE study (2021) (1)
- Impact of Immunochemotherapy with R-Bendamustine or R-CHOP in the Post-Induction Management of Treatment Naïve Advanced Stage Follicular Lymphoma Patients: A Subset Analysis of the FOLL12 Trial By the Fondazione Italiana Linfomi (FIL) (2021) (1)
- 1,2‐dichloroethane conformation and molecular organization in syndiotactic polystyrene gels (2001) (1)
- Darier sign and cutaneous involvement in mastocytosis (2014) (1)
- Transcriptome analysis of primary plasma cell leukemia tumors from a multicenter prospective gimena study : biological and clinical implications (2012) (1)
- Acute lymphoblastic leukemia L3 in Hodgkin's disease in remission. Primitive or secondary leukemia? (1985) (1)
- Quality of Life in Elderly Patients with Acute Myeloid Leukemia Undergoing Induction Chemotherapy (2015) (1)
- TYROSINE KINASE INHIBITORS DISCONTINUATION IN CHRONIC MYELOID LEUKEMIA: A RETROSPECTIVE ANALYSIS OF 208 ITALIAN PATIENTS (2016) (1)
- Prognostic Factors of Response to Erythropoiesis Stimulating Agents (ESA) Treatment in Non RBC Transfusion Dependent Lower Risk MDS. Preliminary Results of a French and Italian Study (on behalf of the GFM and FISM). (2012) (1)
- In male Hodgkin lymphoma patients, impaired fertility may be improved by non‐gonadotoxic therapy (2021) (1)
- On-Demand Plerixafor with Cyclophosphamide and G-CSF for Hematopoietic Stem-Cell Mobilization in Multiple Myeloma Patients: Preliminary Results of a Prospective Observational Study (MOZOBL06877) (2020) (1)
- After Treatment Decrease of Bone Marrow Tregs and Outcome in Younger Patients with Newly Diagnosed Acute Myeloid Leukemia (2020) (1)
- Safety and Efficacy of Rituximab Plus Bendamustine in Relapsed or Refractory Diffuse Large B-Cell Lymphoma Patients (2014) (1)
- Italian Cytometry Society (GIC) endorsement of consensus recommendations for measurable residual disease in chronic lymphocytic leukemia (2021) (1)
- Carfilzomib induction, consolidation, and maintenance with or without autologous stem-cell transplantation in patients with newly diagnosed multiple myeloma: pre-planned cytogenetic subgroup analysis of the randomised, phase 2 FORTE trial. (2022) (1)
- A Randomized Open-Label Study To Evaluate The Efficacy Of Azacitidine For Post-Remission Therapy Of Acute Myeloid Leukemia In Elderly Patients (QOLESS AZA-AMLE) (2013) (1)
- Thermosetting PDLCs: Cure, Morphology and Thermo-Optical Response (1999) (1)
- Single-Cell Sequencing: Ariadne’s Thread in the Maze of Acute Myeloid Leukemia (2022) (1)
- Genome-wide approach identify recurrent 8p21.2 loss in more aggressive form of primary plasma-cell leukemia (2012) (1)
- Lenalidomide-Dexamethasone or Melphalan-Lenalidomide-Prednisone (MPR) or Cyclophosphamide-Prednisone-Lenalidomide (CPR) for Initial treatment of Real Life Elderly Patients with Newly Diagnosed Multiple Myeloma (2015) (1)
- Azacitidine Post-Remission Therapy for Elderly Patients with AML: A Randomized Phase-3 Trial (QoLESS AZA-AMLE) (2023) (0)
- IN MYELOMA PATIENTS TREATED WITH MELPHALAN 100mg/m2 OR MELPHALAN 200mg/m2 OUTCOME IS NOT SIGNIFICANTLY DIFFERENT (2000) (0)
- n Chronic Lymphocytic Leukemia and Autoimmune Diseases (2012) (0)
- comment) All-trans retinoic acid for advanced multiple myeloma (letter; (2012) (0)
- [Antiarrhythmic action of modern local anesthetics. II. Action on experimental arrhythmias induced with adrenaline]. (1969) (0)
- Cutaneous Plasmacytoma Associated with Squamous Cell Carcinoma of the Sacro-Coccygeal Region (2013) (0)
- Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience (2011) (0)
- [Althesin in geriatric injury anesthesia; an evaluation of 100 patients over 70]. (1980) (0)
- Significant Survival Improvement with Maintenance in Patients Achieving a Complete Response: Pooled Analysis of 4 Italian Phase III Trials in Newly Diagnosed Multiple Myeloma Patients (2015) (0)
- APPLICATION of EUTOS SCORE IN CHRONIC Myeloid LEUKEMIA AFFECTING VERY Elderly (>75 years) PATIENTS (2011) (0)
- JAK2 Negative Erythrocytosis Associated with JAK2 GGCC_46/1 Haplotype, Calr rs1049481_G, and Normal Erythropoietin Level: Is This a New Entity? (2020) (0)
- Relevance of hepatitis C virus infection in monoclonal gammopathy (1995) (0)
- [Chemical mediators of pain]. (1969) (0)
- Effect of high-pressure CO2 on polyurethane synthesis (2018) (0)
- Outcome of Soft-Tissue Plasmocytomas in Newly Diagnosed Multiple Myeloma Patients Treated with New Drugs (2018) (0)
- Humoral Immune Response after anti-SARS-CoV-2 Vaccine “Booster” Dose in Patients with Monoclonal Gammopathy of Undetermined Significance (MGUS) (2023) (0)
- Real-Life Analysis of Dasatinib in Chronic Phase CML Patients Aged > 60 Years Resistant/Intolerant to Imatinib. (2009) (0)
- Intensive Chemotherapy Does Not Prolong Survival Compared to 5-Azacitidine in Patients Aged 70 Years or More with Untreated Acute Myeloid Leukemia (2012) (0)
- Treatment with pamidronate in asymptomatic myeloma: results of a pair-matched analysis with historical controls (2000) (0)
- [Description of a case of very serious potassium cyanide poisoning with favorable outcome]. (1971) (0)
- Zoledronate for early-stage, untreated myeloma: An interim report of a randomized study. (2004) (0)
- Measurement of soluble CD4 molecule in chronic lymphoproliferative disorders. (1993) (0)
- Role Of Interim,-PET In Poor Prognosis Young Patients With Diffuse Large B Cell Lymphoma At Diagnosis: Data From An Ancillary Study Of a Prospective Randomized Phase III Study (DLCL04) From the Fondazione Italiana Linfomi (2013) (0)
- IgG and IgA Monoclonal Gammopathies of Undetermined Significance (MGUS) at Low Risk of Evolution: Proposal and Validation of a Prognostic Scoring System (2008) (0)
- [Antiarrhythmic activity of a new local anesthetic (F.I. 6655)]. (1969) (0)
- Nanostructured polymeric molecular sieves (2007) (0)
- Usaturated polyester resins: a study on mechanism and kinetics of the curing process by FTiR spectroscopy (1997) (0)
- Once Weekly Versus Twice Weekly Carfilzomib in Combination with Cyclophosphamide and Dexamethasone in Newly Diagnosed Multiple Myeloma: A Pooled Analysis of Two Phase 1/2 Studies (2018) (0)
- Advances in Multiple Myeloma (2017) (0)
- Effective treatment with cyclosporin A in amegacaryocytic purpura followed by ischemic complications. (1990) (0)
- Chromosome 1 abnormalities in newly diagnosed elderly multiple myeloma patients treated with novel therapies RUNNING HEAD : Chr 1 abnormalities in MM treated with new drugs (2014) (0)
- 322 TET2 mutations, methylation profile and prognosis in higher risk myelodysplastic syndromes (MDS) treated with 5-azacytidine and valproic acid (2011) (0)
- [Hereditary myeloperoxidase deficiency syndrome: clinical and hematologic features of 10 cases]. (1985) (0)
- A Polymeric Crystalline Nanoporous Material for Molecular Packaging (2004) (0)
- Patterns of global DNA methylation identify early stage (Binet A) CLL patients with higher risk of disease progression (2012) (0)
- Evaluation of MRD Status by Flow Cytometry and PCR in Multiple Myeloma Elderly Patients Receiving Autologous Stem Cell Transplantation After Bortezomib-Supplemented Mobilization and Conditioning (2012) (0)
- 198 OUTCOME OF AZACITIDINE TREATMENT AND INCIDENCE OF FEBRILE EVENTS IN “REAL WORLD” PATIENTS WITH MDS OR LOW-BLAST COUNT AML (2015) (0)
- Treatment of relapsed/refractory CLL with Venetoclax-Rituximab during the COVID-19 pandemic: A daily-life experience in southern Italy. (2021) (0)
- Analysis of Stereotyped IGHV Distribution In a Series of 1133 Chronic Lymphocytic Leukemia Patients: The Experience of a Multicenter Italian Study Group (2010) (0)
- Serum C-reactive protein and infections in malignant hematological disorders. (1990) (0)
- Identification of three novel mutations in the PIG-A gene (1996) (0)
- Incidence of Infectious Complications in MDS/AML Patients Treated with Azacitidine By the Italian Cooperative Groups Gruppo Romano MDS (GROM) and Basilicata MDS Registry (2014) (0)
- EVALUATION OF ACCURACY OF "CLLFLOW SCORE" BY AN ESTERNAL VALIDATION MULTICENTER STUDY (2018) (0)
- TP53 Alterations Including Missense Mutations, Aberrant Exon-Junctions and Internal Intron Retentions Are Frequent and May Contribute to MDM2 Antagonist-Resistance in B-Acute Lymphoblastic leukemia (2011) (0)
- Toward the standardization of CD34+ haematopoietic progenitor cell estimation in human umbilical cord blood (1998) (0)
- Gels and clathrates of syndiotactic polystyrene (2002) (0)
- Recombinant human erythropoietin (Rhu-Epo) therapy in low grade myelodysplastic syndromes: Role of cytokines (1994) (0)
- Up-Regulation of Prok-2 in Granulocytes Is Present BOTH in MGUS and MM (2014) (0)
- MicroRNA-155 in serum-derived extracellular vesicles as a potential biomarker for hematologic malignancies - a short report (2016) (0)
- [Evaluation of a new local anesthetic: diphenyl-acetate of 1,alpha-trimethyl-2-piperidyl-carbinol hydrochloride]. (1971) (0)
- Incidence of Cytogenetic Abnormalities in Newly Diagnosed Binet Stage A B-CLL and Relationship with Prognostic Biomarkers: Preliminary Results On 305 Patients Included in the Prospective O-CLL1 GISL Study. (2009) (0)
- Alliance Against Cancer, the network of Italian cancer centers bridging research and care (2015) (0)
- [On the use of Doxapram (3,3-diphenyl-1-ethyl-4-(alpha-morpholino-ethyl)-2-pyrrolidone hydrochloride) in infantile and neonatal anesthesia]. (1970) (0)
- aged 50 to 70: results of a randomized controlled trial Intermediate-dose melphalan improves survival of myeloma patients (2013) (0)
- [Anesthesia in the aged in traumatology and orthopedics]. (1974) (0)
- Leg Type Primary Cutaneous Diffuse Large B-Cell Lymphoma (2018) (0)
- [Role of the vasomotor nervous system in the regulation of pulmonary circulation]. (1969) (0)
- Analisi comparativa di due modelli di staging clinico in 37 casi di mieloma multiplo. (1983) (0)
- SARS-CoV-2 Infection Incidence and Outcome Before and After Full Vaccination in Patients With Monoclonal Gammopathy of Undetermined Significance (2022) (0)
- [Phenotypic shift in blast cells of acute lymphoblastic leukemia during recurrence: biological and clinical implications]. (1988) (0)
- In Vitro Cell Interactions on PVDF Films: Effects of Surface Morphology and Polar Phase Transition (2021) (0)
- Syndromes 5-Azacytidine Efficacy in Higher Risk Myelodysplastic Valproic Acid at Therapeutic Plasma Levels May Increase (2009) (0)
- Unusual Hypergranular Myelomatous Plasma Cells (2017) (0)
- IKAROS in Acute Leukemia: A Positive Influencer or a Mean Hater? (2023) (0)
- Prognostic significance of abdominal CT scan in CLL patients in Binet Stage a : preliminary results of a prospective, multicenter observation –CLL1 - GISL study (2010) (0)
- Thymidine kinase level in cerebrospinal fluid of patients with leukemia (1989) (0)
- [Immunological profile of drug addicts: HTLV-III negative, HTLV-III positive and those with lymphadenopathy syndrome-AIDS related complex]. (1987) (0)
- Deciphering the effects of graft Tregs on chronic graft-versus-host disease: results from a prospective, multicenter study in patients with acute leukemia undergoing allogeneic peripheral blood stem cell transplantation (2022) (0)
- Diffuse B-large cell lymphomas with hepatitis C virus (HCV) infection: An interim report of a comparative study with or without antiviral treatment after chemotherapy (2007) (0)
- Long-Term Analysis of an Open-Label, Multicentre, Randomized Phase 3 Trial Comparing Busulfan Plus Cyclophosphamide Versus Busulfan Plus Fludarabine As a Preparative Regimen for Allogeneic Stem-Cell Transplantation in Patients with Acute Myeloid Leukemia (2022) (0)
- Efficacy of bortezomib in systemic extramedullary localizations of multiple myeloma. (2012) (0)
- Ethylene-Propylene Rubber Bulk Functionalization (1989) (0)
- Gas Storage and Controlled Release by Self-Assembling in Polymer/Gas Clathrate Phases (2006) (0)
- [Considerations on the use of a new respiratory analeptic, doxapram (3,3-diphenyl-1-ethyl-4-(alpha-morpholinoethyl)-2-pyrrolidone chlorydrate) in the differential diagnosis and treatment of post-narcotic apnea]. (1967) (0)
- 298 DEFERASIROX COULD IMPROVE HEMATOPOIESIS IN MYELODYSPLASTIC SYNDROMES BY AFFECTING REDOX SIGNALING IN HEMATOPOIETIC STEM CELLS (2015) (0)
- multiple myeloma: updated results of a randomized controlled trial Oral melphalan, prednisone, and thalidomide in elderly patients with (2013) (0)
- Epoxy-bismaleimide systems : network development and structure, and effect of these on water interactions and thermal-oxidative stability (2000) (0)
- P138 Valproic acid at therapeutic plasma levels may increase 5-azacitidine efficacy in higher risk myelodysplastic syndromes (2009) (0)
- hematopoietic progenitor cells : a five dimensional flow cytometric study (2005) (0)
- Reduced Intensity Conditioning Regimen for Allografting Following Cytoreductive Autografting in Relapsed/Resistant Hodgkin’s Lymphoma. (2004) (0)
- P893: CARFILZOMIB IN COMBINATION WITH LENALIDOMIDE AND DEXAMETHASONE (KRD) AS SALVAGE THERAPY FOR MULTIPLE MYELOMA PATIENTS: ITALIAN, MULTICENTER, RETROSPECTIVE EXPERIENCE OUTSIDE OF CLINICAL TRIALS (2022) (0)
- Transport of low-molecular-weight c: ompounds in silicalpolyimide hybrids (2005) (0)
- Insightsintodefibrotide:an updatedreview (2009) (0)
- Six Years of Experience and Outcome with Maintenance Therapy with Very Low Dose Thalidomide after Auto-SCT in Multiple Myeloma (2008) (0)
- Real Life, Retrospective Analysis of Bortezomib Re-Use As Second Treatment for Relapsed Multiple Myeloma Patients Previously Exposed to Bortezomib-Based Therapies As First Line: The Rebound Study (2016) (0)
- The Impact of Imaging Techniques Based on Vibrational Spectroscopy on the Molecular Characterization of Syndiotactic Polystyrene Co-Crystals (2011) (0)
- Genome-Wide Analysis of Primary Plasma-Cell Leukemia Identifies Recurrent Imbalances Associated with Transcriptional Profile Alterations (2011) (0)
- A063 Reduced-Intensity Conditioning Allogeneic Stem Cell Transplantation in Myeloma: A Prospective Trial (2009) (0)
- Optical Fiber Tip Functionalized by Colloidal Photonic Crystal and Gold Nano-Particles for SERS Sensing (2020) (0)
- Rare HVR1-HCV genotype 1b variants in patients with B non Hodgkin's lymphoma. Comparison with viral sequences detected in cases of lymphoproliferative disorders and B cell compartmentalisation. (2007) (0)
- PF585 GENE-EXPRESSION PROFILE OF HIGH-DENSITY NEUTROPHILS REVEALS PROGRESSIVE DIFFERENCES IN MGUS AND MULTIPLE MYELOMA, ASSOCIATED WITH REDUCED PHAGOCYTOSIS AND INCREASED INFECTION SUSCEPTIBILITY (2019) (0)
- A Case-Control Study on the Role of an Antiviral Treatment with Interferon and Ribavirin after Conventional Chemotherapy in Diffuse Large B-Cell Lymphomas with Hepatitis C Virus (HCV) Infection (2008) (0)
- P18: DARATUMUMAB (D) PLUS BORTEZOMIB (V) AND DEXAMETHASONE (D) AS SALVAGE THERAPY FOR PATIENTS WITH REFRACTORY/RELAPSED MULTIPLE MYELOMA (RRMM): INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY “RETE EMATOLOGICA PUGLIESE” (2022) (0)
- Place in therapy of innovative drugs in multiple myeloma in 2021 and 2023 according to an expert panel Delphi consensus (2021) (0)
- Phenotypic shift in blast cells of acute lymphoblastic leukemia at relapse: Clinical and biological implications (1988) (0)
- Antiviral treatment with interferon +/- ribavirin after chemotherapy for diffuse large B-cell non-Hodgkin lymphomas with hepatitis C virus (HCV) infection (2007) (0)
- Redox Signaling in Adult Stem Cell Biology: A New Target Controlling Pluripotency and Differentiation. What about Iron Chelators?. (2012) (0)
- Survival Risk Scores for Real-Life Relapsed/Refractory Multiple Myeloma Patients Receiving Elotuzumab or Carfilzomib In Combination With Lenalidomide and Dexamethasone as Salvage Therapy: Analysis of 919 Cases Outside Clinical Trials (2022) (0)
- Predicting poor peripheral blood stem cell collection in patients with multiple myeloma receiving pre-transplant induction therapy with novel agents and mobilized with cyclophosphamide plus granulocyte-colony stimulating factor: results from a Gruppo Italiano Malattie EMatologiche dell’Adulto Multip (2015) (0)
- [Intraoperative diagnosis of pulmonary embolism by the measurement of carbon dioxide]. (1991) (0)
- Orientation control of low molecular weight guest molecules into nanoporous crystalline polymer films (2004) (0)
- Pseudomembranous colitis in acute lymphoblastic leukaemia (2018) (0)
- pH activated colloidal Nanospheres: A viable sensing platform for the Therapeutic Drug Monitoring of the anticancer Drug 6-Mercaptopurine (2021) (0)
- P1084: CHECK-POINT INHIBITORS IN PATIENTS WITH RELAPSE/REFRACTORY HODGKIN’S LYMPHOMA: A RETROSPECTIVE ANALYSYS BY THE RETE EMATOLOGICA PUGLIESE (REP). (2022) (0)
- Italian Real Life Experience with Brentuximab Vedotin: Results of a National Observational Study on Relapsed/Refractory Hodgkin's Lymphoma (2016) (0)
- Diffuse Large B-Cell Lymphomas (DLBCL) with Hepatitis-C Virus (HCV) Infection: Incidence, Clinical Outcome and Preliminary Results of Antiviral Treatments (AVT) after Chemotherapy. (2006) (0)
- Immune Suppression By High-Density Neutrophils Predicts Short Progression-Free Survival in Multiple Myeloma (2016) (0)
- Reduced Intensity Conditioning Regimen for Allografting Following Autografting Is Feasible and Has a Strong Anti Multiple Myeloma Activity. (2004) (0)
- Editorial: Polymer Chemistry Editor’s Pick 2021 (2021) (0)
- Serological Response to BNT162b2 Anti-Sars-Cov-2 mRNA Vaccine in Patients with Transfusion Dependent Thalassemia (2021) (0)
- Soluble intercellular adhesion molecule-1 correlates with markers of disease activity in B-cell chronic lymphocytic leukemia. (1995) (0)
- Intercrosslinked polymer networks by simultaneous curing of unsaturated polyesters and bismaleimide resins (1994) (0)
- Management of patients with multiple myeloma and COVID-19 in the post pandemic era: a consensus paper from the European Myeloma Network (EMN). (2023) (0)
- Label-Free Protein Analysis by Pyro-Electrohydrodynamic Jet Printing of Gold Nanoparticles (2022) (0)
- case-control study Hepatitis C virus and B-cell non-Hodgkin lymphomas: an Italian multicenter (2013) (0)
- 253 Insights on centromeric breakpoints of 5q deletions (2011) (0)
- Thalidomide and Dexamethasone Is an Effective Salvage Regimen for Myeloma Patients Relapsing after Autologous Transplant. (2004) (0)
- Plerixafor with biosimilar granulocyte colony-stimulating factor (G-CSF): effective strategy in peripheral blood stem cell (PBSC) mobilization in poor mobilizers (2014) (0)
- [Biological and clinical significance of plasma-cell acid phosphatase in multiple myeloma]. (1986) (0)
- Inclusion of Total BODY Computed Tomography (TB-CT) SCANS In the INITIAL WORK-up of Binet STAGE A CHRONIC LYMPHOCYTIC LEUKEMIA (CLL) PATIENTS On CLINICAL Grounds: PRELIMINARY RESULTS of the Prospective, MULTICENTER O-CLL1- GISL STUDY (2011) (0)
- MPT Vs ThaDD in Very Elderly Patients with Multiple Myeloma: a Case-Match Study (2009) (0)
- [Cytogenetic aspects of short-term cell cultures of lymph node, bone marrow, peripheral blood and serous effusion cells from 325 cases of Hodgkin's disease]. (1984) (0)
- New treatment strategies for elderly myeloma patients (2009) (0)
- Design and application of a novel PNA probe for the detection at single cell level of JAK2V617Fmutation in Myeloproliferative Neoplasms (2013) (0)
- Long term follow-up of refractory/relapsed acute myeloid leukemia patients treated with the FLAG-Ida regimen as bridge therapy to allotransplantation: 10-year results from a single centre experience. (2023) (0)
- EphA3 targeting reduces in vitro adhesion and invasion and in vivo growth and angiogenesis of multiple myeloma cells (2017) (0)
- P1319: T AND B LYMPHOCYTES SUBSETS AFTER BNT162B2 ANTI-SARS-COV-2 M-RNA VACCINATION: A COMPARISON BETWEEN HEMATOPOIETIC STEM CELL TRANSPLANTATION PATIENTS AND HEALTHY CONTROLS. (2022) (0)
- Therapy-Related Myeloid Neoplasms: Report Of The Italian Network On Secondary Leukemias. (2013) (0)
- EFFECT OF a IFN ON UNAGGRESSIVE IMMUNOPROLIFERATIVE DISORDERS (2005) (0)
- A Real-Life Study of Deferasirox in Patients with Higher Risk Myelodysplastic Syndromes (2017) (0)
- Hypereosinophilia with a pinch of salt and pepper (2021) (0)
- High Serum Levels of Extracellular Vesicles which Express Specific Markers of Malignancy Are Released in Patients with Various Types of Hematological Neoplastic Disorders (2014) (0)
- Impact on Tumour Treatment and Outcome of Sars-Cov-2 Infection in 91 Patients with Primary CNS Lymphoma: A Real-Life Study of the International PCNSL Collaborative Group (2022) (0)
- Complete Response to First-Line Bortezomib-Thalidomide-Dexamethasone Therapy in Multiple Myeloma Patients with t(4;14): Analysis of Gene Expression Profile. (2009) (0)
- Long-Term Carfilzomib for High-Risk Patients with Newly Diagnosed Multiple Myeloma: A Pooled Analysis of Two Phase 1/2 Studies (2018) (0)
- A refined composite clinical score for the early identification of the predicted Poor Mobilizers (PM): a GITMO analysis. (2015) (0)
- A Novel Denaturing-High Performance Liquid Chromatography (D-HPLC)-Based Method for Kit Mutation Screening of Patients (pts) with Systemic Mastocytosis (SM) Allows the Identification of Unreported Kit Variants. (2006) (0)
- Role of Acute Myeloid Leukemia Derived-Extracellular Vesicles in Dysregulating Normal Hematopoiesis (2019) (0)
- Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study (2022) (0)
- 181 HIGH SERUM LEVELS OF EXTRACELLULAR VESICLES ARE RELEASED IN PATIENTS WITH MYELODYSPLASTIC SYNDROME AND ACUTE MYELOID LEUKEMIA (2015) (0)
- Incidence of Cytogenetic Abnormalities In Newly Diagnosed Binet Stage A CLL and Relationship with Prognostic Biomarkers and with Stereotyped B Cell Receptors: Updated Results on 344 Patients Included In the Prospective O-CLL1 GISL Study. (2010) (0)
- Purging in Vivo and Auto-Transplantation in Patients with Poor Prognosis Lymphoproliferative Disease (2008) (0)
- [Cardiac toxicity of a new local anesthetic (F.I. 6655). Electrocardiographic study]. (1969) (0)
- A Score Model for Predicting Unsuccessful or Sub-Optimal Peripheral Blood Stem Cell Collections in Multiple Myeloma Based on a Retrospective Analysis of 1,039 Patients Receiving Novel Agents As Induction Therapy and Cyclophosphamide Plus G-CSF As Mobilizing Regimen, (2011) (0)
- A real-world analysis of PD1 blockade from the Rete Ematologica Pugliese (REP) in patients with relapse/refractory Hodgkin’s lymphoma (2023) (0)
- P077 Adaptation and changes in quality of life in patients with myelodysplastic syndrome (2009) (0)
- 252 NPM1 haploinsufficiency in human myeloid diseases with non-isolated −5/5q- (2011) (0)
- [Emergencies in the mountains: is a multifunctional monitoring possible?]. (1991) (0)
- PF602 OUTCOME OF EXTRA-MEDULLARY DISEASE IN NEWLY DIAGNOSED MULTIPLE MYELOMA PATIENTS TREATED WITH NEW DRUGS (2019) (0)
- Deferasirox drives ROS-mediated differentiation and induces interferon-stimulated gene expression in human healthy haematopoietic stem/progenitor cells and in leukemia cells (2019) (0)
- Chlorinated guest orientation and mobility in the clathrate phase structure with syndiotactic polystyrene (2002) (0)
- Electro-optical properties of an epoxy-based polymer-dispersed liquid crystal (1999) (0)
- Clofarabine (2022) (0)
- Surface-enhanced Raman spectroscopy on engineered plasmonic metamaterials for “label free” biosensing (2015) (0)
- Myelodysplastic Syndromes with Hypocellular Marrow: Clinical Characteristics and Evaluation of Outcome (2018) (0)
- [Glycoprotein P-170, associated with multidrug resistance, in patients with acute leukemia in complete remission]. (1991) (0)
- [Anesthesia in patients with chronic renal insufficiency for orthopedic-traumatology surgery. Clinical contribution]. (1987) (0)
- Evaluation of Atypical Low Energy Fractures in Patients Affected by Multiple Myeloma Treated with Bispohosphonates (2011) (0)
- Prognostic Implication of Somatic Mutations by Next Generation Sequencing: an Analysis from the MMRF CoMMpass Study in Newly Diagnosed Multiple Myeloma Patients (2016) (0)
- Natural ageing of automotive polymer components: characterisation of new and used car bumpers (2002) (0)
- ANALYSIS OF SPERMATOGENESIS BEFORE AND AFTER TREATMENT IN PATIENTS WITH HODGKIN LYMPHOMA (2021) (0)
- Survey on Adsorption of Low Molecular Weight Compounds in Cu-BTC Metal–Organic Framework: Experimental Results and Thermodynamic Modeling (2022) (0)
- Immunochemical Characterization of the Specific Sequence of URG7 Protein (2016) (0)
- Chapter 1 Epoxy resins (1996) (0)
- P-159: Effectiveness of anti-SARS-CoV-2 vaccine “booster” dose in patients with multiple myeloma (2022) (0)
- DNA methylation dynamic of bone marrow hematopoietic stem cells after allogeneic transplantation (2019) (0)
- Soluble intercellular adhesion molecule-1 correlates with markers of disease activity in B-cell chronic lymphocytic leukemia [letter; comment] (1995) (0)
- Francesco Lo Coco, a distinguished hematologist and a friend (2019) (0)
- High-density neutrophils in MGUS and multiple myeloma are dysfunctional and immune-suppressive due to increased STAT3 downstream signaling (2020) (0)
- “Normal Vibrational Analysis of semicrystalline polymers:experimental determination of transition moment vectors” (2009) (0)
- Recycling of Plastic Car Components: Multilayer Items based on Polypropylene (2000) (0)
- Oral Antiviral Therapy and Monoclonal Antibody for the Treatment of COVID-19 Infection in Outpatients Receiving Anti-Cancer Treatment for Hematological Malignancies: A Multicenter Prospective Study Exploring Efficacy, Safety and Predictors of COVID-19 Lung Failure (2022) (0)
- Maintenance Therapy vs Re-treatment at Biochemical Relapse vs Observation in Relapsed/Refractory Multiple Myeloma Patients: Results of a Phase II, Randomized Study (2019) (0)
- CHARLSON COMORBIDITIES INDEX (CCI) MAY PREDICT COMPLIANCE AND DEVELOPMENT OF PLEURAL EFFUSIONS IN ELDERLY CHRONIC MYELOID LEUKEMIA (CML) RESISTANT/INTOLERANT PATIENTS TREATED WITH DASATINIB (2010) (0)
- Using rHuG-CSF in Multiple Myeloma: Consolidated Data, Evolutions, and New Concepts (2012) (0)
- Association of amifostine and erythropoietin for the treatment of anemia in myelodysplastic syndromes (2000) (0)
- LONG-TERM FOLLOW-UP AND SAFETY OF DASATINIB IN CML/ALL PH1+IMATINIB RESISTANT PATIENTS IN A COMPASSIONATE USEPROGRAM (2009) (0)
- Immunocytochemical typing of fine needle aspirates by means of alkaline phosphatase anti-alkaline phosphatase method. A study of 16 selected patients (1989) (0)
- Predictive Factors for Overall Survival in Chronic Myeloid Leukemia Patients: An Analysis By the Gimema Cml Italian Study (2020) (0)
- Systemic Mastocytosis. A GIMEMA Multicenter Survey. (2006) (0)
- Daratumumab plus bortezomib or daratumumab plus lenalidomide as salvage therapy for patients with myeloma: initial follow-up of an Italian multicentre retrospective clinical experience by ‘Rete Ematologica Pugliese’ (2022) (0)
- 149 LOW RPS14 EXPRESSION IS FREQUENTLY FOUND IN NON-5Q-MYELODYSPLASTIC SYNDROMES (2015) (0)
- of 1175 patients overall survival in elderly myeloma treated with novel agents: analysis Complete response correlates with long-term progression-free and (2012) (0)
- High-Density Neutrophils are Immunosuppressive in Multiple Myeloma Due to Increased Arginase-1, Predictor of Short Progression Free Survival (2016) (0)
- Polymeric Molecular Sieves for Environmental Protection (2007) (0)
- Molecular Features and Diagnostic Challenges in Alpha/Beta T-Cell Large Granular Lymphocyte Leukemia (2022) (0)
- The Poor Outcome of Multiple Myeloma (MM) Patients Carrying At Diagnosis Deleted TP53 and or Amplified MDM4 Might Be Related to the Deregulation of Genes Involved in Cell Cycle Control and DNA Damage Repair (2012) (0)
- Prognostic Role of CDKN2A Deletion and p53 Expression and Association With MIPIb in Mantle Cell Lymphoma. (2023) (0)
- P145 A meta-analysis of the published studies and the long-term results of a large personal experience form the basis for an appropriate use of thalidomide in myelodysplastic syndromes (2007) (0)
- Complementary and alternative medicine use in patients with chronic lymphocytic leukemia: a multicentric italian survey (2012) (0)
- Implications of Interleukin-6 (IL-6)-blockade for severe COVID-19 infection in patients with Multiple Myeloma (2021) (0)
- Real-World Efficacy and Safety of Luspatercept in Adult Patients with Transfusion-Dependent Anaemia Due to Lower-Risk Myelodysplastic Syndromes with Ring Sideroblasts (MDS-RS), Who Had an Unsatisfactory Response to or are Ineligible for Erythropoiesis Stimulating Agents: A Retrospective, Multicenter (2022) (0)
- P564: FINAL RESULTS OF THE QOLESS AZA-AMLE RANDOMIZED TRIAL TO EVALUATE THE EFFICACY OF 5-AZA FOR POST-REMISSION THERAPY OF ACUTE MYELOID LEUKEMIA IN ELDERLY PATIENTS (2022) (0)
- Bortezomib-dexamethasone as maintenance therapy or early retreatment at biochemical relapse versus observation in relapsed/refractory multiple myeloma patients: a randomized phase II study (2020) (0)
- Clinical Outcomes of 420 MDS Patients Treated with 5-Azacytidine: Evaluation of Overall Survival, Duration of Treatment and Rate of Discontinuation in a Real Life Study from the Italian MDS Registry of Fondazione Italiana Sindromi Mielodisplastiche (FISM) (2016) (0)
- Efficacy of Lenalidomide in Primary Plasma Cell Leukemia. (2007) (0)
- [Antiarrhythmic action of modern local anesthetics. I. Action on experimental arrhythmias induced with ouabain]. (1969) (0)
- Higher Versus Standard Doses of Recombinant Erythropoietin for the Treatment of Anemia in Patients with Myelodysplastic Syndromes: Results of a Retrospective Survey from the Italian Registry of Myelodisplastic Syndromes (FISM) (2016) (0)
- The Combination of Frailty and ISS Scores Identifies a Simple Prognostic Index for Overall Survival in Elderly Patients Treated with Novel Agents-Based Induction Therapy (2014) (0)
- The genomic analysis brings a new piece to the molecular jigsaw of idiopathic erythrocytosis (2022) (0)
- Polymer Chemistry Editor’s Pick 2021 (2021) (0)
- Tumor Microenvironment and Microvascular Density in Follicular Lymphoma (2022) (0)
- Relapse of chronic myeloid leukemia in lymphoid crisis after allogeneic bone marrow transplantation in chronic phase with a busulfan plus cyclophosphamide regimen (2002) (0)
- A Crumbled but Fatal Acute Leukemia (2021) (0)
- A case of Zanoli and Vecchi postoperative convulsive syndrome. (1974) (0)
- [Theoretical aspects of renal elimination via non-ionic diffusion of acids and weak bases]. (1968) (0)
- Plasma cell leukemia: another piece of the puzzle (2022) (0)
- [Neuroleptic malignant syndrome. Problems of differential diagnosis. Description of a clinical case]. (1992) (0)
- [Our experience with a new synthetic analgesic preparation: WIN 20,228 (pentazocine)]. (1969) (0)
- Self-transparency effect of a laser beam propagating in a polymer dispersal liquid crystal (2000) (0)
- Inside the biology of early T-cell precursor acute lymphoblastic leukemia: the perfect trick (2021) (0)
- Blastic plasmacytoid dendritic cell leukemia: preliminary results of a retrospective italian multicentric study. (2011) (0)
- Chapter 2 Unsaturated polyester resins (1996) (0)
- Lenalidomide Plus Dexamethasone Versus Lenalidomide Plus Melphalan and Prednisone: A Case-Control Study in Newly Diagnosed Elderly Myeloma Patients. (2009) (0)
- [Changes in the arterioveous O2 gradient following to intravenous administration of methyldiazepinone]. (1969) (0)
- Achievement of European standards by CROB-IRCCS. (2015) (0)
- [Use of a pharyngo-tracheal cannula in emergency ventilation; functional evaluation]. (1991) (0)
- P17: DARATUMUMAB (D) PLUS LENALIDOMIDE (R) AND DEXAMETHASONE (D) AS SALVAGE THERAPY FOR PATIENTS WITH REFRACTORY-RELAPSED MULTIPLE MYELOMA (RRMM): INITIAL FOLLOW-UP OF AN ITALIAN MULTICENTER RETROSPECTIVE CLINICAL EXPERIENCE BY “RETE EMATOLOGICA PUGLIESE” (2022) (0)
- O-020 Erythropoietin alpha therapy in 1110 lower-risk MDS patients: A real life survey from the network of regional Italian MDS Registries (2013) (0)
- OXIDATIVE STRESS IN CHRONIC LYMPHOCYTIC LEUKEMIA (2016) (0)
- Gold Photonic Crystals and Photonics Quasi-crystals for Reproducible Surface-Enhanced Raman Substrates (2015) (0)
- [Use of sulpiride in ketamine anesthesia]. (1976) (0)
- Integration of total body CT scan in the initial work-up of binet stage a CLL patients on clinical grounds : preliminary results of a prospective multicenter observational-CLL1 Gisl study (2010) (0)
- RELATIONSHIP BETWEEN CYTOGENETIC ANOMALIES AND BIOMARKERS IN BINET STAGE A PATIENTS WITH CHRONIC LYMPHOCYTIC LEUKEMIA AT DIAGNOSIS: PRELIMINARY RESULTS OF A PROSPECTIVE, MULTICENTER O-CLL1 GISL STUDY (2009) (0)
- Effect Of Deferasirox On Reactive Species Of Oxygen (ROS) Production In Hematopoietic Stem Cells: Up Or Down? (2013) (0)
- Occurrence of chronic myeloid leukemia in a patient with CDC73 gene deletion: “Chance or Causality?” (2021) (0)
- A case of acute promyelocytic leukemia variant with derivative chromosome 3 der(3)t(3;8) associated with 8q partial gain (2019) (0)
- A Pyrazolo[3,4-d]Pyrimidine Compound Reduces Fyn Phosphorylation and Induces Apoptosis in Large Granular Lymphocyte Leukemia Cells (2015) (0)
- 795 Protein Pathway Activation Mapping of KRAS Mutated NSCLC Clinical Samples Reveals Systemic Pathway Alterations and Point to New Therapeutic Targets for EGFR Resistant Tumors (2012) (0)
- A105 A Phase III Study of MEL200 Versus MEL100 in Newly Diagnosed Myeloma Young Patients (2009) (0)
- DEFERASIROX DRIVES ROS-MEDIATED DIFFERENTIATION AND INDUCES INTERFERON-STIMULATED GENES EXPRESSION IN HEALTHY HEMATOPOIETIC STEM/PROGENITOR CELLS AND IN LEUKEMIA CELLS: PF464 (2019) (0)
- [Determination of thymidine kinase in the cerebrospinal fluid as a marker of leukemic meningosis]. (1989) (0)
- Comparison between azacitidine and decitabine as front-line therapy in elderly acute myeloid leukemia patients not eligible for intensive chemotherapy. (2023) (0)
- Co-Occurrence of High-Risk Lesions Is a Consistent Predictor of Ultra-High Risk Multiple Myeloma in Newly Diagnosed and Relapsed/Refractory Patients - Meta-Analysis of 5,808 Trial Patients (2022) (0)
- Real-world Outcomes of Relapsed/Refractory Diffuse Large B-cell Lymphoma Treated With Polatuzumab Vedotin-based Therapy (2022) (0)
- [Comparative analysis of 2 clinical staging systems in 37 cases of multiple myeloma]. (1983) (0)
- 205 Circulating regulatory T cells (Tregs) in myelodysplastic syndromes (MDS) (2011) (0)
- [IgG kappa/IgA lambda biclonal gammopathy. Demonstration of the involvement of 2 different plasma-cell clones using anti-idiotypic antibodies]. (1986) (0)
- PB2130 REAL-WORLD ITALIAN EXPERIENCE OF POMALIDOMIDE IN RELAPSED-REFRACTORY MYELOMA: RETROSPECTIVE MULTICENTER STUDY BY THE RETE EMATOLOGICA PUGLIESE AND BASILICATA (2019) (0)
- Synergistic e ff ect of desferrioxamine and recombinant erythropoietin on erythroid precursor proliferation in chronic renal failure (1999) (0)
- Prospective, Case-Control Study of Serological Response after Two Doses of BNT162b2 anti-SARS-CoV-2 mRNA Vaccine in Transfusion-Dependent Thalassemic Patients (2022) (0)
- Identification of EpHA3 As a New Potential Molecular Target in Multiple Myeloma. (2012) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Pellegrino Musto?
Pellegrino Musto is affiliated with the following schools:
